<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation - Bray, JJH - 2023 | Cochrane Library</title> <meta content="Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation - Bray, JJH - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013765.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation - Bray, JJH - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013765.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013765.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation" name="citation_title"/> <meta content="Jonathan JH Bray&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Oxford University Hospitals Trust, John Radcliffe Hospital, Headley Way, Headington" name="citation_author_institution"/> <meta content="jonathanjhbray@gmail.com" name="citation_author_email"/> <meta content="Mazhar Warraich&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Walsall Healthcare NHS Trust" name="citation_author_institution"/> <meta content="Michael G Whitfield&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Christina Udani Peter&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Addenbrookes Hospital (Cambridge University Hospitals)" name="citation_author_institution"/> <meta content="Ranu Baral" name="citation_author"/> <meta content="University of East Anglia" name="citation_author_institution"/> <meta content="Mahmood Ahmad" name="citation_author"/> <meta content="Royal Free Hospital, Royal Free London NHS Foundation Trust" name="citation_author_institution"/> <meta content="Shazaib Ahmad" name="citation_author"/> <meta content="St Helier Hospital" name="citation_author_institution"/> <meta content="George R Abraham" name="citation_author"/> <meta content="Royal Free Hospital" name="citation_author_institution"/> <meta content="Ali Kirresh" name="citation_author"/> <meta content="Royal Free Hospital" name="citation_author_institution"/> <meta content="Muhammad Salman Sahibzada" name="citation_author"/> <meta content="Calderdale Royal Hospital" name="citation_author_institution"/> <meta content="Adnan Muzaffar" name="citation_author"/> <meta content="Scunthrope General Hospital" name="citation_author_institution"/> <meta content="Joseph Tomson" name="citation_author"/> <meta content="Royal Free Hospital" name="citation_author_institution"/> <meta content="Pier D Lambiase" name="citation_author"/> <meta content="The Heart Hospital, University College London Hospitals" name="citation_author_institution"/> <meta content="Gabriella Captur" name="citation_author"/> <meta content="Amitava Banerjee" name="citation_author"/> <meta content="University College London" name="citation_author_institution"/> <meta content="Rui Providencia" name="citation_author"/> <meta content="St Bartholomew's Hospital, Barts Health NHS Trust" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD013765.pub2" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/03/13" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013765.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013765.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013765.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anti-Arrhythmia Agents [adverse effects]; *Atrial Fibrillation [drug therapy, surgery]; *Catheter Ablation [adverse effects]; *Heart Failure [drug therapy]; *Myocardial Infarction" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013765.pub2&amp;doi=10.1002/14651858.CD013765.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013765.pub2&amp;doi=10.1002/14651858.CD013765.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013765.pub2&amp;doi=10.1002/14651858.CD013765.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013765.pub2&amp;doi=10.1002/14651858.CD013765.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013765.pub2&amp;doi=10.1002/14651858.CD013765.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013765.pub2&amp;doi=10.1002/14651858.CD013765.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013765.pub2&amp;doi=10.1002/14651858.CD013765.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013765.pub2&amp;doi=10.1002/14651858.CD013765.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013765.pub2&amp;doi=10.1002/14651858.CD013765.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013765.pub2&amp;doi=10.1002/14651858.CD013765.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013765.pub2&amp;doi=10.1002/14651858.CD013765.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013765.pub2&amp;doi=10.1002/14651858.CD013765.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013765.pub2&amp;doi=10.1002/14651858.CD013765.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013765.pub2&amp;doi=10.1002/14651858.CD013765.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013765.pub2&amp;doi=10.1002/14651858.CD013765.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013765.pub2&amp;doi=10.1002/14651858.CD013765.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013765.pub2&amp;doi=10.1002/14651858.CD013765.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013765.pub2&amp;doi=10.1002/14651858.CD013765.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013765.pub2&amp;doi=10.1002/14651858.CD013765.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013765.pub2&amp;doi=10.1002/14651858.CD013765.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013765.pub2&amp;doi=10.1002/14651858.CD013765.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013765.pub2&amp;doi=10.1002/14651858.CD013765.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013765.pub2&amp;doi=10.1002/14651858.CD013765.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="wbKFI7vu";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013765\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013765\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013765\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013765\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","ru","ko","th","ms","fa","pl","fr","ro"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013765.pub2",title:"Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation",firstPublishedDate:"Mar 13, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Heart Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=wbKFI7vu&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013765.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013765.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013765.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013765.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013765.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013765.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ro&quot;,&quot;title&quot;:&quot;Sumar&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013765.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013765.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013765.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013765.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3996 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013765.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013765.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013765.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013765.pub2/full#CD013765-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013765.pub2/full#CD013765-sec-0099"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013765.pub2/full#CD013765-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013765.pub2/full#CD013765-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013765.pub2/full#CD013765-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013765.pub2/full#CD013765-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013765.pub2/full#CD013765-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013765.pub2/full#CD013765-sec-0093"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013765.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013765.pub2/appendices#CD013765-sec-0105"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013765.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013765.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/supinfo/CD013765StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/supinfo/CD013765StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013765.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013765.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013765.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013765.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013765.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013765.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="These authors contributed equally to this work as first authors."><a href="/cdsr/doi/10.1002/14651858.CD013765.pub2/information#CD013765-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Jonathan JH Bray</a><sup>a</sup></li> <li class="author custom-tooltip" title="These authors contributed equally to this work as first authors."><a href="/cdsr/doi/10.1002/14651858.CD013765.pub2/information#CD013765-cr-0005">Mazhar Warraich</a><sup>a</sup></li> <li class="author custom-tooltip" title="These authors contributed equally to this work as second authors."><a href="/cdsr/doi/10.1002/14651858.CD013765.pub2/information#CD013765-cr-0006">Michael G Whitfield</a><sup>a</sup></li> <li class="author custom-tooltip" title="These authors contributed equally to this work as second authors."><a href="/cdsr/doi/10.1002/14651858.CD013765.pub2/information#CD013765-cr-0007">Christina Udani Peter</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013765.pub2/information#CD013765-cr-0008">Ranu Baral</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013765.pub2/information#CD013765-cr-0009">Mahmood Ahmad</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013765.pub2/information#CD013765-cr-0010">Shazaib Ahmad</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013765.pub2/information#CD013765-cr-0011">George R Abraham</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013765.pub2/information#CD013765-cr-0012">Ali Kirresh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013765.pub2/information#CD013765-cr-0013">Muhammad Salman Sahibzada</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013765.pub2/information#CD013765-cr-0014">Adnan Muzaffar</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013765.pub2/information#CD013765-cr-0015">Joseph Tomson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013765.pub2/information#CD013765-cr-0016">Pier D Lambiase</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013765.pub2/information#CD013765-cr-0017">Gabriella Captur</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013765.pub2/information#CD013765-cr-0018">Amitava Banerjee</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013765.pub2/information#CD013765-cr-0019">Rui Providencia</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/information/en#CD013765-sec-0109">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 13 March 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013765.pub2">https://doi.org/10.1002/14651858.CD013765.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013765-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013765-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013765-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013765-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013765-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013765-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD013765-abs-0008">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013765-abs-0001" lang="en"> <section id="CD013765-sec-0001"> <h3 class="title" id="CD013765-sec-0001">Background</h3> <p>Recurrence of atrial tachyarrhythmias (ATa) following catheter ablation for atrial fibrillation (AF) is a common problem. Antiarrhythmic drugs have been used shortly after ablation in an attempt to maintain sinus rhythm, particularly Class I and III agents. However, it still needs to be established if the use of Class I or III antiarrhythmic medications, or both, reduce the risk of recurrence of ATa. </p> </section> <section id="CD013765-sec-0002"> <h3 class="title" id="CD013765-sec-0002">Objectives</h3> <p>To assess the effects of oral Class I and III antiarrhythmic drugs versus control (standard medical therapy without Class I or III antiarrhythmics, or placebo) for maintaining sinus rhythm in people undergoing catheter ablation for AF. </p> </section> <section id="CD013765-sec-0003"> <h3 class="title" id="CD013765-sec-0003">Search methods</h3> <p>We systematically searched CENTRAL, MEDLINE, Embase, Web of Science Core Collection, and two clinical trial registers without restrictions on language or date to 5 August 2022. </p> </section> <section id="CD013765-sec-0004"> <h3 class="title" id="CD013765-sec-0004">Selection criteria</h3> <p>We sought published, unpublished, and ongoing parallel‐design, randomised controlled trials (RCTs) involving adult participants undergoing ablation for AF, with subsequent comparison of Class I and/or III antiarrhythmic use versus control (standard medical therapy or non‐Class I and/or III antiarrhythmic use). </p> </section> <section id="CD013765-sec-0005"> <h3 class="title" id="CD013765-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane and performed meta‐analyses with risk ratios (RR) and Peto odds ratios (Peto OR). Our primary outcomes were recurrence of atrial tachyarrhythmias; adverse events: thromboembolic events; adverse events: myocardial infarction; adverse events: new diagnosis of heart failure; and adverse events: requirement for one or more hospitalisations for atrial tachyarrhythmia. Our secondary outcomes were: all‐cause mortality; and requirement for one or more repeat ablations. Where possible, we performed comparison analysis by Class I and/or III antiarrhythmic and divided follow‐up periods for our primary outcome. We performed comprehensive assessments of risk of bias and certainty of evidence applying the GRADE methodology. </p> </section> <section id="CD013765-sec-0006"> <h3 class="title" id="CD013765-sec-0006">Main results</h3> <p>We included nine RCTs involving a total of 3269 participants. Participants were on average 59.3 years old; 71.0% were male; and 72.9% and 27.4% had paroxysmal and persistent AF, respectively. Class I and/or III antiarrhythmics may reduce recurrence of ATa at 0 to 3 months postablation (risk ratio (RR) 0.74, 95% confidence interval (CI) 0.59 to 0.94, 8 trials, 3046 participants, low‐certainty evidence) and likely reduce recurrence at &gt; 3 to 6 months, our a priori primary time point (RR 0.85, 95% CI 0.78 to 0.93, 5 trials, 2591 participants, moderate‐certainty evidence). Beyond six months the evidence is very uncertain, and the benefit of antiarrhythmics may not persist (RR 1.14, 95% CI 0.84 to 1.55, 4 trials, 2244 participants, very low‐certainty evidence). The evidence suggests that Class I and/or III antiarrhythmics may not increase the risk of thromboembolic events, myocardial infarction, all‐cause mortality, or requirement for repeat ablation, at 0 to 3, &gt; 3 to 6, and &gt; 6 months (where data were available; low‐ to very low‐certainty evidence). The use of Class I and/or III antiarrhythmics postablation likely reduces hospitalisations for ATa by approximately 57% at 0 to 3 months (RR 0.43, 95% CI 0.28 to 0.64, moderate‐certainty evidence). No data were available beyond three months. No data were available on new diagnoses of heart failure. </p> <p>Fewer data were available for Class I and III antiarrhythmics individually. Based on only one and two trials (n = 125 to 309), Class I antiarrhythmics may have little effect on recurrence of ATa at 0 to 3, &gt; 3 to 6, and &gt; 6 months (RR 0.88, 95% CI 0.64 to 1.20, 2 trials, 309 participants; RR 0.54, 95% CI 0.25 to 1.19, 1 trial, 125 participants; RR 0.87, 95% CI 0.57 to 1.32, 1 trial, 125 participants; low‐certainty evidence throughout); requirement for hospitalisation for ATa at 0 to 3 months (low‐certainty evidence); or requirement for repeat ablation at 0 to 3 months (low‐certainty evidence). No data were available for thromboembolic events, myocardial infarction, new diagnosis of heart failure, or all‐cause mortality at any time points, or hospitalisation or repeat ablation beyond three months. </p> <p>Class III antiarrhythmics may have little effect on recurrence of ATa at up to 3 months and at &gt; 3 to 6 months (RR 0.76, 95% CI 0.50 to 1.16, 4 trials, 599 participants, low‐certainty evidence; RR 0.82, 95% CI 0.62 to 1.09, 2 trials, 318 participants, low‐certainty evidence), and beyond 6 months one trial reported a possible increase in recurrence of ATa (RR 1.95, 95% CI 1.29 to 2.94, 1 trial, 112 participants, low‐certainty evidence). Class III antiarrhythmics likely reduce hospitalisations for ATa at 0 to 3 months (RR 0.40, 95% CI 0.26 to 0.63, moderate‐certainty evidence), and may have little effect on all‐cause mortality (low‐ to very low‐certainty evidence). The effect of Class III antiarrhythmics on thromboembolic events and requirement for repeat ablation was uncertain (very low‐certainty evidence for both outcomes). No data were available for myocardial infarction or new diagnosis of heart failure at any time point, outcomes other than recurrence beyond 6 months, or for hospitalisation and repeat ablation &gt; 3 to 6 months. </p> <p>We assessed the majority of included trials as at low or unclear risk of bias. One trial reported an error in the randomisation process, raising the potential risk of selection bias; most of the included trials were non‐blinded; and two trials were at high risk of attrition bias. </p> </section> <section id="CD013765-sec-0007"> <h3 class="title" id="CD013765-sec-0007">Authors' conclusions</h3> <p>We found evidence to suggest that the use of Class I and/or III antiarrhythmics up to 3 months after ablation is associated with a reduced recurrence of ATa 0 to 6 months after ablation, which may not persist beyond 6 months, and an immediate reduction in hospitalisation for ATa 0 to 3 months after ablation. The evidence suggests there is no difference in rates of all‐cause mortality, thromboembolic events, or myocardial infarction between Class I and/or III antiarrhythmics versus control. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013765-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013765-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD013765-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD013765-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013765-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013765-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013765-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013765-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD013765-abs-0013">Polski</a> </li> <li class="section-language"> <a class="" href="full/ro#CD013765-abs-0016">Română</a> </li> <li class="section-language"> <a class="" href="full/ru#CD013765-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD013765-abs-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013765-abs-0004">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013765-abs-0002" lang="en"> <h3>Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation </h3> <p><b>Review question</b> </p> <p>We wanted to find out how effective certain classes of antiarrhythmic drugs (medications used to prevent or treat an irregular heart rhythm) are for maintaining sinus rhythm (normal heart rhythm) in people after catheter ablation (a technique using catheters to create controlled burns in the heart to prevent and treat arrhythmia occurrence) for atrial fibrillation (a common type of irregular heart rhythm), compared to catheter ablation alone. </p> <p><b>Background</b> </p> <p>The most common abnormal heart rhythm, atrial fibrillation can cause the upper two chambers of the heart (atria) to beat very rapidly leading to symptoms such as palpitations, dizziness, and shortness of breath. Treatment of atrial fibrillation typically includes medications to control the heart rate and reduce the risk of stroke. However, in some people, restoring the normal heart rhythm to control symptoms is achieved by creating controlled burns with ablation catheters to eliminate atrial fibrillation. Patients often revert back to atrial fibrillation despite ablation, and certain antiarrhythmic drugs (of which we were only interested in Class I and III) are given to reduce the risk of recurrence of arrhythmia. </p> <p><b>Selection criteria</b> </p> <p>We performed a thorough search of databases for all trials including atrial fibrillation and all individual Class I and Class III antiarrhythmic drugs including, for example, flecainide, propafenone, amiodarone, dronedarone, and sotalol. </p> <p><b>Study characteristics</b> </p> <p>We conducted the search on 5 August 2022, and identified 4682 citations (papers), out of which nine were eligible randomised controlled trials (a type of study where people are randomly assigned to one of two or more treatment groups). The studies included a total of 3269 participants from six countries, who were assigned to either Class I or III antiarrhythmics (or both) or placebo (sugar pill)/standard treatment. People taking part in the studies were on average 59 years old, and 71% were male. Most people had paroxysmal atrial fibrillation (meaning they were not in atrial fibrillation all the time and alternated with normal rhythms). </p> <p><b>Results</b> </p> <p>We found that the effect of Class I and/or III antiarrhythmic drugs given up to around 3 months after ablation may reduce recurrence of arrhythmia at 0 to 3 months, and likely reduces recurrence at greater than 3 to 6 months, although the benefit does not appear to continue beyond 6 months (the evidence for this last result was very uncertain). We also looked at adverse outcomes (i.e. complications). We found that the use of antiarrhythmics was probably associated with a reduction in hospitalisation at 0 to 3 months. We also found evidence suggesting that antiarrhythmics are not associated with different rates of thromboembolic events (clots in the brain, lungs, or legs), heart attacks, death due to any cause, or requirement for repeat ablation compared with control or standard treatment. </p> <p><b>Certainty of the results</b> </p> <p>Our confidence in the evidence was low for recurrence of arrhythmias at 0 to 3 months, moderate at 3 to 6 months, and very low at greater than 6 months. Our confidence in the evidence for reduction of hospitalisation for arrhythmias was moderate. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013765-sec-0099" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013765-sec-0099"></div> <h3 class="title" id="CD013765-sec-0100">Implications for practice</h3> <section id="CD013765-sec-0100"> <p>Catheter ablation is a costly procedure with the risks associated with invasive procedures. Trying to maintain sinus rhythm after ablation through antiarrhythmics has thus been a strategy that has been used clinically. In practice, this is limited by the selection, duration, and dosing of medications. Our review shows that the effects of antiarrhythmics, despite only being used for three months in the analysed studies, persisted beyond three months but not beyond six months. The fact that rehospitalisations are also reduced in the first three months with antiarrhythmics adds to the evidence for their usage. </p> <p>Our review may add to the evidence for Class I and III antiarrhythmic usage for people postablation; nonetheless, this needs to be a decision tailored clinically to each patient due to limitations in our understanding of complications such as thromboembolism, myocardial infarction, and new diagnosis of heart failure. There is also less evidence for the effects of these drugs beyond six months, although this may be due to the fact that they were stopped at three months in the included studies. </p> <p>It is clear that people undergoing atrial fibrillation (AF) ablation have improved quality of life postablation and have a significant reduction in AF burden (<a href="./references#CD013765-bbs2-0054" title="Blomstrom-LundqvistC , GizurarsonS , SchwielerJ , JensenSM , BergfeldtL , KennebackG , et al. Effect of catheter ablation vs antiarrhythmic medication on quality of life in patients with atrial fibrillation: the CAPTAF randomized clinical trial. JAMA2019;321:1059–68.">Blomstrom‐Lundqvist 2019</a>). This is why the European Society of Cardiology (ESC) has changed its recommendations from antiarrhythmics as first‐line therapy, and if failing this then undergoing ablation in symptomatic paroxysmal AF, to "AF catheter ablation should be considered before a trial of [antiarrhythmics] in patients with paroxysmal AF episodes (Class IIa), or maybe considered in patients with persistent AF without risk factors for recurrence (Class IIb)". This has clinical implications, as patients referred for ablation will not necessarily be on antiarrhythmics before ablation. Our meta‐analysis suggests that due to effects outside of the blanking period (i.e. the initial three months) and the reduction in hospitalisation in the first three months, these patients may still be considered for antiarrhythmics if they are undergoing ablation for maintenance of sinus rhythm. </p> <p>The ESC also states that: "a. Continuing [antiarrhythmic] treatment for 6 weeks to 3 months may reduce early AF recurrences, rehospitalizations and cardioversions during this period. Clinical practice regarding routine [antiarrhythmic] treatment after ablation varies and there is no convincing evidence that such treatment is routinely needed" (<a href="./references#CD013765-bbs2-0080" title="HindricksG , PotparaT , DagresN , ArbeloE , BaxJJ , Blomström-LundqvistC , et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. European Heart Journal2021;42(5):373–498. [DOI: 10.1093/eurheartj/ehaa612]">Hindricks 2020</a>). </p> <p>The latest American Heart Association (AHA) guidance does not provide a recommendation on this question (<a href="./references#CD013765-bbs2-0081" title="JanuaryCT , WannLS , CalkinsH , ChenLY , CigarroaJE , Cleveland JC Jr, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation2019;140:e125–51.">January 2019a</a>). </p> <p>This review provides low‐ to moderate‐certainty evidence that Class I and/or III antiarrhythmics during the blanking period reduce the recurrence of atrial tachyarrhythmias up to six months after the ablation. It is increasingly clear that Class I and/or III antiarrhythmics are probably beneficial when given during the blanking period. </p> <p>Hospitalisation post‐AF has also been a major problem, with one study in the USA involving 811 participants reporting that 9.7% were hospitalised within 30 days of ablation and 19.1% had a visit to Accident and Emergency (<a href="./references#CD013765-bbs2-0068" title="FreemanJV , TabadaGH , ReynoldsK , SungSH , LiuTI , GuptaN . Contemporary procedural complications, hospitalizations, and emergency visits after catheter ablation for atrial fibrillation. American Journal of Cardiology2018;121(5):602-8. [DOI: 10.1016/j.amjcard.2017.11.034]">Freeman 2018</a>). At one year, 28.9% of participants were readmitted and 44.5% were seen in Accident and Emergency (<a href="./references#CD013765-bbs2-0068" title="FreemanJV , TabadaGH , ReynoldsK , SungSH , LiuTI , GuptaN . Contemporary procedural complications, hospitalizations, and emergency visits after catheter ablation for atrial fibrillation. American Journal of Cardiology2018;121(5):602-8. [DOI: 10.1016/j.amjcard.2017.11.034]">Freeman 2018</a>). Guo and colleagues have already shown that AF ablation results in a 56% reduction in hospitalisation postablation (<a href="./references#CD013765-bbs2-0074" title="GuoJ , NayakHM , BesserSA , BeaserA , AzizZ , BromanM , et al. Impact of atrial fibrillation ablation on recurrent hospitalization: a nationwide cohort study. Journal of American College of Cardiology: Clinical Electrophysiology2019;5(3):330–9.">Guo 2019</a>). Another study by Aurora and colleagues reported that 16.5% of ablation patients were readmitted within 90 days (<a href="./references#CD013765-bbs2-0053" title="AroraS , LahewalaS , TripathiB , MehtaV , KumarV , ChandramohanD , et al. Causes and predictors of readmission in patients with atrial fibrillation undergoing catheter ablation: a national population-based cohort study. Journal of the American Heart Association2018;7(12):e009294.">Arora 2018</a>). Since one of the main benefits of AF ablation is reduction in hospitalisation, the fact that this meta‐analysis shows some benefit in reduction in hospitalisation provides further evidence for Class I and/or III antiarrhythmic usage. </p> </section> <h3 class="title" id="CD013765-sec-0101">Implications for research</h3> <section id="CD013765-sec-0101"> <p>The available evidence is limited by the lack of systematic assessment in the majority of studies of important clinical outcomes such as all‐cause mortality, thromboembolic events, and myocardial infarction. Future trials investigating antiarrhythmics (Class I and III) should measure their effects on such clinical outcomes. Given the moderate heterogeneity in ablation strategies utilised between included studies, further work should endeavour to standardise ablation strategies to assess antiarrhythmic efficacy as well as matching for demographic factors. </p> <p>We believe a large, multicentre trial is needed to further clarify this question. Firstly, the vast majority of included randomised controlled trials were not blinded, and secondly there was variability in the results of the included studies. Due to these limitations, additional data from a large, multicentre randomised study is required with important clinical outcomes such as myocardial infraction, all‐cause mortality, and thromboembolic events. This study should also compare different periods of antiarrhythmics usage, such as less than three months to up to a year. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013765-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013765-sec-0008"></div> <div class="table" id="CD013765-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Class I and/or III antiarrhythmics versus control for maintaining sinus rhythm after catheter ablation of atrial fibrillation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Class I and/or III antiarrhythmics versus control for maintaining sinus rhythm after catheter ablation of atrial fibrillation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patients or population:</b> Human trial participants undergoing ablation for atrial fibrillation </p> <p><b>Settings:</b> Community and healthcare settings </p> <p><b>Intervention:</b> Class I and/or III antiarrhythmics </p> <p><b>Comparison:</b> Standard medical therapy or placebo postablation not including Class I or III antiarrhythmics </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes at &gt; 3 to 6 months after ablation</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects*<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> <p><b>NNTB (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo or no treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Class I/III antiarrhythmic drugs</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recurrence of atrial tachyarrhythmias</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>453 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>385 per 1000</p> <p>(353 to 421)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.85 (0.78 to 0.93)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2591 (5 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁⨁◯</p> <p>MODERATE<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 15 (10 to 32)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events: thromboembolic events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> <p>(1 to 155)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 0.96 (0.06 to 15.50)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>212 (1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>VERY LOW<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events: myocardial infarction</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No data available at &gt; 3 to 6 months, but available at &gt; 6 months<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events: new diagnosis of heart failure</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No data available at any time point<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events: requirement for 1 or more hospitalisations for atrial tachyarrhythmia</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No data available at &gt; 3 to 6 months, but available at 0 to 3 months<sup>e</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000</p> <p>(1 to 357)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 1.00 (0.06 to 16.24)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 (1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯</p> <p>LOW<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Requirement for 1 or more repeat ablations</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No data available at &gt; 3 to 6 months, but available at 0 to 3 months and &gt; 6 months<sup>g</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% confidence interval) is calculated based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Outcomes at time points other than primary time point of interest (&gt; 3 to 6 months)</b> </p> <p><sup>a</sup>Recurrence of atrial tachyarrhythmias: 0 to 3 months: RR 0.74 (0.59 to 0.94); &gt; 6 months: RR 1.14 (0.84 to 1.55).<br/><sup>b</sup>Thromboembolic events: 0 to 3 months: not estimable; &gt; 6 months: Peto OR 2.74 (0.39 to 19.5).<br/><sup>c</sup>Myocardial infarction: 0 to 3 months: not available; &gt; 6 months: Peto OR 1.01 (0.06 to 16.09).<br/><sup>d</sup>New diagnosis of heart failure: 0 to 3 months: not available; &gt; 6 months: not available.<br/><sup>e</sup>Hospitalisations for atrial tachyarrhythmia: 0 to 3 months: RR 0.43 (0.28 to 0.64); &gt; 6 months: not available.<br/><sup>f</sup>All‐cause mortality: 0 to 3 months: Peto OR 0.13 (0.00 to 6.57); &gt; 6 months: Peto OR 1.50 (0.26 to 8.68).<br/><sup>g</sup>Repeat ablation: 0 to 3 months: RR 1.10 (0.61 to 2.00); &gt; 6 months: RR 0.95 (0.79 to 1.13). </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level for risk of bias, regarding exclusion of participants lost to follow‐up in <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>, and randomisation generation and allocation concealment in <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>.<br/><sup>2</sup>Downgraded for imprecision (two levels) (95% CI 0.06 to 15.5, which is consistent with both appreciable benefit and appreciable harm, and low event numbers) and risk of bias, specifically concerning exclusion of participants lost to follow‐up in <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a> (one level).<br/><sup>3</sup>Downgraded for imprecision (one level) (95% CI 0.06 to 16.2, which is consistent with both appreciable benefit and appreciable harm) and risk of bias, specifically concerning exclusion of participants lost to follow‐up in <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a> (one level). </p> <p>Outcomes have been downgraded twice for imprecision where there are few events and the 95% CI include both appreciable benefit and harm. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013765-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Class I antiarrhythmics versus control for maintaining sinus rhythm after catheter ablation of atrial fibrillation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Class I antiarrhythmics versus control for maintaining sinus rhythm after catheter ablation of atrial fibrillation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patients or population:</b> Human trial participants undergoing ablation for atrial fibrillation </p> <p><b>Settings:</b> Community and healthcare settings </p> <p><b>Intervention:</b> Class I antiarrhythmics </p> <p><b>Comparison:</b> Standard medical therapy or placebo postablation not including Class I or III antiarrhythmics </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes at &gt; 3 to 6 months after ablation</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects*<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo or no treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Class I antiarrhythmic drugs</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recurrence of atrial tachyarrhythmias</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>238 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>129 per 1000</p> <p>(60 to 283)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.54 (0.25 to 1.19)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125 (1 trial)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>LOW<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events: thromboembolic events</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events: myocardial infarction</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events: new diagnosis of heart failure</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events: requirement for 1 or more hospitalisations for atrial tachyarrhythmia</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available at &gt; 3 to 6 months, but available at 0 to 3 months<sup>e</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available<sup>f</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Requirement for 1 or more repeat ablation</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available at &gt; 3 to 6 months, but available at 0 to 3 months<sup>g</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% confidence interval) is calculated based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Outcomes at time points other than primary time point of interest (&gt; 3 to 6 months)</b> </p> <p><sup>a</sup>Recurrence of atrial tachyarrhythmias: 0 to 3 months: RR 0.88 (0.64 to 1.20); &gt; 6 months: RR 0.87 (0.57 to 1.32).<br/><sup>b</sup>Thromboembolic events: 0 to 3 months: not available; &gt; 6 months: not available.<br/><sup>c</sup>Myocardial infarction: 0 to 3 months: not available; &gt; 6 months: not available.<br/><sup>d</sup>New diagnosis of heart failure: 0 to 3 months: not available; &gt; 6 months: not available.<br/><sup>e</sup>Hospitalisations for atrial tachyarrhythmia: 0 to 3 months: RR 0.34 (0.01 to 8.28); &gt; 6 months: not available.<br/><sup>f</sup>All‐cause mortality: 0 to 3 months: not available; &gt; 6 months: not available.<br/><sup>g</sup>Repeat ablation: 0 to 3 months: RR 0.88 (0.51 to 1.53); &gt; 6 months: not available. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded two levels for imprecision (95% CI 0.25 to 1.19, which is consistent with both appreciable benefit and appreciable harm) and not meeting the optimal information size. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013765-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Class III antiarrhythmics versus control for maintaining sinus rhythm after catheter ablation of atrial fibrillation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Class III antiarrhythmics versus control for maintaining sinus rhythm after catheter ablation of atrial fibrillation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patients or population:</b> Human trial participants undergoing ablation for atrial fibrillation </p> <p><b>Settings:</b> Community and healthcare settings </p> <p><b>Intervention:</b> Class III antiarrhythmics </p> <p><b>Comparison:</b> Standard medical therapy or placebo postablation not including Class I or III antiarrhythmics </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes at &gt; 3 to 6 months after ablation</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects*<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo or no treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Class III antiarrhythmic drugs</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recurrence of atrial tachyarrhythmias</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>413 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>339 per 1000</p> <p>(256 to 450)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.82 (0.62 to 1.09)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>318 (2 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯</p> <p>LOW<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events: thromboembolic events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> <p>(1 to 155)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 0.96 (0.06 to 15.50)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>212 (1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯</p> <p>VERY LOW<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events: myocardial infarction</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events: new diagnosis of heart failure</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events: requirement for 1 or more hospitalisations for atrial tachyarrhythmia</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available at &gt; 3 to 6 months, but available at 0 to 3 months<sup>e</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000</p> <p>(0 to 66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 0.13 (0.00 to 6.57)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>212 (1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯</p> <p>VERY LOW<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Requirement for 1 or more repeat ablation</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>No data available at &gt; 3 to 6 months, but available at 0 to 3 months<sup>g</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% confidence interval) is calculated based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Outcomes at time points other than primary time point of interest (&gt; 3 to 6 months)</b> </p> <p><sup>a</sup>Recurrence of atrial tachyarrhythmias: 0 to 3 months: RR 0.76 (0.50 to 1.16); &gt; 6 months: RR 1.95 (1.29 to 2.94).<br/><sup>b</sup>Thromboembolic events: 0 to 3 months: not estimable; &gt; 6 months: not available.<br/><sup>c</sup>Myocardial infarction: 0 to 3 months: not available; &gt; 6 months: not available.<br/><sup>d</sup>New diagnosis of heart failure: 0 to 3 months: not available; &gt; 6 months: not available.<br/><sup>e</sup>Hospitalisations for atrial tachyarrhythmia: 0 to 3 months: RR 0.40 (0.26 to 0.63); &gt; 6 months: not available.<br/><sup>f</sup>All‐cause mortality: 0 to 3 months: Peto OR 1.00 (0.06 to 16.24); &gt; 6 months: not available.<br/><sup>g</sup>Repeat ablation: 0 to 3 months: RR 1.18 (0.66 to 2.11); &gt; 6 months: not available. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for imprecision (one level) (95% CI 0.62 to 1.09, which is consistent with both appreciable benefit and appreciable harm) and risk of bias, specifically concerning exclusion of participants lost to follow‐up in <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a> (one level).<br/><sup>2</sup>Downgraded for imprecision (two levels) (95% CI 0.06 to 15.5, which is consistent with both appreciable benefit and appreciable harm, and low event numbers) and risk of bias concerning exclusion of participants lost to follow‐up in <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a> (one level).<br/><sup>3</sup>Downgraded for imprecision (two levels) (95% CI 0.00 to 6.57, which is consistent with both appreciable benefit and appreciable harm, and low event numbers) and risk of bias concerning exclusion of participants lost to follow‐up in <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a> (one level). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013765-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013765-sec-0009"></div> <section id="CD013765-sec-0010"> <h3 class="title" id="CD013765-sec-0010">Description of the condition</h3> <p>Atrial fibrillation (AF) is the most commonly occurring abnormal heart rhythm condition. It is associated with increased morbidity and mortality through strokes caused by blood clots and also through association with failure of the left lower chamber (ventricle) of the heart (<a href="./references#CD013765-bbs2-0088" title="MarkidesV , SchillingRJ . Atrial fibrillation: classification, pathophysiology, mechanisms and drug treatment. Heart2003;89(8):939-43. [DOI: 10.1136/heart.89.8.939]">Markides 2003</a>; <a href="./references#CD013765-bbs2-0097" title="PoonK , OkinPM , KligfieldP . Diagnostic performance of a computer-based ECG rhythm algorithm. Journal of Electrocardiology2005;38(3):235-8.">Poon 2005</a>). Recent data from the UK demonstrate an increase in the prevalence of AF by 50% from 2000 to 2016, meaning that the condition now affects 3.3% of the general practice population aged 35 years or older (<a href="./references#CD013765-bbs2-0052" title="AdderleyNJ , RyanR , NirantharakumarK , MarshallT . Prevalence and treatment of atrial fibrillation in UK general practice from 2000 to 2016. Heart2019;105(1):27-33.">Adderley 2019</a>). The worldwide prevalence of 0.5% (33.5 million individuals) is likely to be underestimated, given the large proportion of asymptomatic and undiagnosed individuals (<a href="./references#CD013765-bbs2-0096" title="PatelNJ , AttiV , MitraniRD , Viles-GonzalezJF , GoldbergerJJ . Global rising trends of atrial fibrillation: a major public health concern. Heart2018;104:1989-90.">Patel 2018</a>). </p> <p>There are multiple risk factors for AF, including, for example, structural heart disease, both inherited and secondary to hypertension, ischaemia or valvular heart disease, hyperthyroidism, and high body mass index (BMI), whilst AF without risk factors is only seen in 15% of AF cases (<a href="./references#CD013765-bbs2-0088" title="MarkidesV , SchillingRJ . Atrial fibrillation: classification, pathophysiology, mechanisms and drug treatment. Heart2003;89(8):939-43. [DOI: 10.1136/heart.89.8.939]">Markides 2003</a>). Typically the abnormal electrical activity of AF arises from the muscle layer of the pulmonary veins into the left atrium of the heart (<a href="./references#CD013765-bbs2-0088" title="MarkidesV , SchillingRJ . Atrial fibrillation: classification, pathophysiology, mechanisms and drug treatment. Heart2003;89(8):939-43. [DOI: 10.1136/heart.89.8.939]">Markides 2003</a>). People presenting with new‐onset AF can be treated with rate control with or without anticoagulation, depending on their risk for stroke (<a href="./references#CD013765-bbs2-0084" title="KirchhofP , BenussiS , KotechaD , AhlssonA , AtarD , CasadeiB , et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Revista Española de Cardiología [Spanish Journal of Cardiology]2017;70(1):50.">Kirchhof 2017</a>). Rate control, through the use of beta blockers, calcium channel blockers or digoxin, may be appropriate for people with hypertension, structural heart disease, and permanent AF. However, in some people, such as those with severe symptoms, who do not benefit from rate control therapy, or who prefer to reduce their burden of AF, the AF needs to be eliminated and a normal heart rate (e.g. normal sinus rhythm) restored (<a href="./references#CD013765-bbs2-0055" title="BorianiG , ProiettiM . Atrial fibrillation prevention: an appraisal of current evidence. Heart2018;104:882-7.">Boriani 2018</a>). </p> <p>Atrial tachyarrhythmias (ATa), including AF, atrial flutter, or atrial tachycardias, can occur after ablation. In atrial flutter or macroreentrant tachycardias, an electrical signal propagates in a circular motion around the atrium, causing the atria to beat much faster than the ventricles. Focal atrial tachycardias originate and propagate from a localised ectopic focus in the atria (<a href="./references#CD013765-bbs2-0084" title="KirchhofP , BenussiS , KotechaD , AhlssonA , AtarD , CasadeiB , et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Revista Española de Cardiología [Spanish Journal of Cardiology]2017;70(1):50.">Kirchhof 2017</a>). </p> </section> <section id="CD013765-sec-0011"> <h3 class="title" id="CD013765-sec-0011">Description of the intervention</h3> <p>Rhythm control in AF is achieved by chemical cardioversion using antiarrhythmic drugs, electrical cardioversion, or cardiac ablation therapy (<a href="./references#CD013765-bbs2-0084" title="KirchhofP , BenussiS , KotechaD , AhlssonA , AtarD , CasadeiB , et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Revista Española de Cardiología [Spanish Journal of Cardiology]2017;70(1):50.">Kirchhof 2017</a>). Ablation therapy has emerged as an alternative in symptomatic or drug‐resistant patients, and it is well established that catheter ablation is superior to oral antiarrhythmic drugs alone for rhythm control (<a href="./references#CD013765-bbs2-0075" title="HaegeliL , CalkinsH . Catheter ablation of atrial fibrillation: an update. European Heart Journal2014;35(36):2454–9. [DOI: 10.1093/eurheartj/ehu291]">Haegeli 2014</a>). Catheter ablation uses a catheter to identify the abnormal electrical triggers causing AF, which are then neutralised using radiofrequency impulses or other methods (<a href="./references#CD013765-bbs2-0075" title="HaegeliL , CalkinsH . Catheter ablation of atrial fibrillation: an update. European Heart Journal2014;35(36):2454–9. [DOI: 10.1093/eurheartj/ehu291]">Haegeli 2014</a>). Consensus guidelines recommend catheter ablation for paroxysmal and persistent AF, class I and IIa recommendations respectively (<a href="./references#CD013765-bbs2-0057" title="CalkinsH , HindricksG , CappatoG , KimYN , SaadE , AguinagaL , et al. HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. Journal of Arrhythmia2017;33(5):369–409. [DOI: 10.1016/j.joa.2017.08.001]">Calkins 2017</a>; <a href="./references#CD013765-bbs2-0082" title="JanuaryCT , WannLS , CalkinsH , ChenLY , CigarroaJE , ClevelandJC . 2019 AHA/ACC/HRS focused update of the 2014 guideline for management of patients with atrial fibrillation. Journal of the American College of Cardiology2019;74(1):104-32.">January 2019b</a>). There are multiple modalities for delivering cardiac ablation, with the best evidence supporting radiofrequency ablation and cryoablation (<a href="./references#CD013765-bbs2-0080" title="HindricksG , PotparaT , DagresN , ArbeloE , BaxJJ , Blomström-LundqvistC , et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. European Heart Journal2021;42(5):373–498. [DOI: 10.1093/eurheartj/ehaa612]">Hindricks 2020</a>). The 2020 European Society of Cardiology (ESC) AF guidelines, based on level A evidence (meaning a strong recommendation for clinicians), recommend catheter ablation of symptomatic paroxysmal AF to improve AF symptoms in people with symptomatic recurrences (<a href="./references#CD013765-bbs2-0056" title="BurnsPB , RohrichRJ , ChungKC . The levels of evidence and their role in evidence-based medicine. Plastic Reconstructive Surgery2011;128(1):305-10. [DOI: 10.1097/PRS.0b013e318219c171]">Burns 2011</a>; <a href="./references#CD013765-bbs2-0080" title="HindricksG , PotparaT , DagresN , ArbeloE , BaxJJ , Blomström-LundqvistC , et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. European Heart Journal2021;42(5):373–498. [DOI: 10.1093/eurheartj/ehaa612]">Hindricks 2020</a>; <a href="./references#CD013765-bbs2-0084" title="KirchhofP , BenussiS , KotechaD , AhlssonA , AtarD , CasadeiB , et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Revista Española de Cardiología [Spanish Journal of Cardiology]2017;70(1):50.">Kirchhof 2017</a>). </p> <p>The Vaughan‐Williams classification divides antiarrhythmic drugs into five classes based on their electrophysiological action (effect on ion channels), as follows. </p> <p> <ol id="CD013765-list-0001"> <li> <p>Class I agents interfere with the sodium (Na<sup>+</sup>) channel. </p> </li> <li> <p>Class II agents are antisympathetic agents (beta‐blockers).</p> </li> <li> <p>Class III agents affect potassium (K<sup>+</sup>) efflux. </p> </li> <li> <p>Class IV agents affect calcium channels and the atrioventricular (AV) node.</p> </li> <li> <p>Class V agents work by other or unknown mechanisms.</p> </li> </ol> </p> <p>In addition to having other actions, oral Class I and Class III drugs slow the repolarisation of cardiac myocytes which increases the refractory period, making them effective in rhythm control (<a href="./references#CD013765-bbs2-0086" title="LeiM , WuL , TerrarDA , HaungCL . Modernized classification of cardiac antiarrhythmic drugs. Circulation2018;138(17):1879-96.">Lei 2018</a>). Drugs that belong to other classes are often used in rate control and are less relevant for this review. </p> </section> <section id="CD013765-sec-0012"> <h3 class="title" id="CD013765-sec-0012">How the intervention might work</h3> <p>Prolonged AF causes structural and physiological changes that enable AF to subsist. Failure to maintain normal rhythm after ablation is not uncommon, and thus postprocedural antiarrhythmic medications (generally Class I and III agents) have been thought to prevent recurrence of AF when used after ablation. People with early relapses in the 'blanking period' (a period of approximately three months in which occurrences of ATa ‐ including AF, atrial flutter, or atrial tachycardias ‐ after ablation are possible due to periprocedural inflammation and not considered as a true ablation failure) are thought to be more likely to relapse. These ATa are rhythms that originate from the atrium as a consequence of abnormal electrical activity and may represent a failure of the ablation treatment. Patients can become relapse‐free after the inflammation from the ablation subsides (<a href="./references#CD013765-bbs2-0109" title="WillemsS , KhairyP , AndradeJG , HoffmannBA , LevesqueS , VermaA , et al. Redefining the blanking period after catheter ablation for paroxysmal atrial fibrillation: insights from the ADVICE (Adenosine following pulmonary Vein Isolation to target dormant Conduction Elimination) trial. Circulation: Arrhythmia and Electrophysiology2016;9:8.">Willems 2016</a>). Antiarrhythmic drugs may play a role in reducing early relapses in the blanking period during electrophysiological reorganisation or in the period immediately after the blanking period (three to six months and long term), and thus reduce recurrences postablation. There are fewer data on intermediate follow‐up (i.e. the time between the blanking period and long‐term follow‐up), which is an area that requires analysis (<a href="./references#CD013765-bbs2-0109" title="WillemsS , KhairyP , AndradeJG , HoffmannBA , LevesqueS , VermaA , et al. Redefining the blanking period after catheter ablation for paroxysmal atrial fibrillation: insights from the ADVICE (Adenosine following pulmonary Vein Isolation to target dormant Conduction Elimination) trial. Circulation: Arrhythmia and Electrophysiology2016;9:8.">Willems 2016</a>). AF ablation is associated with a significant reduction in hospitalisation, with Guo and colleagues showing a 56% reduction in hospitalisation in the first year after AF ablation (<a href="./references#CD013765-bbs2-0074" title="GuoJ , NayakHM , BesserSA , BeaserA , AzizZ , BromanM , et al. Impact of atrial fibrillation ablation on recurrent hospitalization: a nationwide cohort study. Journal of American College of Cardiology: Clinical Electrophysiology2019;5(3):330–9.">Guo 2019</a>). Class I and III antiarrhythmic agents can be well‐tolerated; however, side effects are a serious concern (<a href="./references#CD013765-bbs2-0088" title="MarkidesV , SchillingRJ . Atrial fibrillation: classification, pathophysiology, mechanisms and drug treatment. Heart2003;89(8):939-43. [DOI: 10.1136/heart.89.8.939]">Markides 2003</a>). A recent Cochrane Review raised concerns about possible harm by sotalol following cardioversion, with one additional death observed for every 102 participants treated with sotalol for one year (<a href="./references#CD013765-bbs2-0108" title="ValemboisL , AudureauE , TakedaA , JarzebowskiW , BelminJ , Lafuente‐LafuenteC . Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database of Systematic Reviews2019, Issue 9. Art. No: CD005049. [DOI: 10.1002/14651858.CD005049.pub5]">Valembois 2019</a>). Amiodarone in particular causes severe toxicity of the lungs, liver, and eyes, amongst many other adverse effects. Class I drugs are pro‐arrhythmic and can also cause toxicity in multiple other body systems (<a href="./references#CD013765-bbs2-0098" title="RehmanSU , SiddiquiN , KhanNS , SobiaR , AssalyR . Multisystem side effects of amiodarone. American Journal of the Medical Sciences2015;349(5):454.">Rehman 2015</a>). </p> </section> <section id="CD013765-sec-0013"> <h3 class="title" id="CD013765-sec-0013">Why it is important to do this review</h3> <p>Previous meta‐analyses have disputed whether antiarrhythmic drugs are protective at reducing the rate of recurrence of ATa (<a href="./references#CD013765-bbs2-0070" title="GoldenbergGR , BurdD , LodzinskiP , StabileG , UdellJA , NewmanD , et al. Antiarrhythmic therapy as an adjuvant to promote postpulmonary vein isolation success - a meta-analysis. Journal of Interventional Cardiac Electrophysiology: an International Journal of Arrhythmias and Pacing2016;47(2):171-6.">Goldenberg 2016</a>; <a href="./references#CD013765-bbs2-0110" title="XuX , AlidaCT , YuB . Administration of antiarrhythmic drugs to maintain sinus rhythm after catheter ablation for atrial fibrillation: a meta-analysis. Cardiovascular Therapeutics2015;33(4):242-6. [DOI: 10.1111/1755-5922.12133]">Xu 2015</a>). Goldenberg and colleagues found that short‐term antiarrhythmics after pulmonary vein isolation appeared not to reduce recurrence of ATa (<a href="./references#CD013765-bbs2-0070" title="GoldenbergGR , BurdD , LodzinskiP , StabileG , UdellJA , NewmanD , et al. Antiarrhythmic therapy as an adjuvant to promote postpulmonary vein isolation success - a meta-analysis. Journal of Interventional Cardiac Electrophysiology: an International Journal of Arrhythmias and Pacing2016;47(2):171-6.">Goldenberg 2016</a>), whereas Xu and colleagues in 2015 concluded that antiarrhythmic drugs reduced the early reoccurrence of AF after catheter ablation by more than 50%, but no significant differences were observed for late reoccurrence (<a href="./references#CD013765-bbs2-0110" title="XuX , AlidaCT , YuB . Administration of antiarrhythmic drugs to maintain sinus rhythm after catheter ablation for atrial fibrillation: a meta-analysis. Cardiovascular Therapeutics2015;33(4):242-6. [DOI: 10.1111/1755-5922.12133]">Xu 2015</a>). Neither reviews performed detailed subgroup analysis (<a href="./references#CD013765-bbs2-0070" title="GoldenbergGR , BurdD , LodzinskiP , StabileG , UdellJA , NewmanD , et al. Antiarrhythmic therapy as an adjuvant to promote postpulmonary vein isolation success - a meta-analysis. Journal of Interventional Cardiac Electrophysiology: an International Journal of Arrhythmias and Pacing2016;47(2):171-6.">Goldenberg 2016</a>; <a href="./references#CD013765-bbs2-0110" title="XuX , AlidaCT , YuB . Administration of antiarrhythmic drugs to maintain sinus rhythm after catheter ablation for atrial fibrillation: a meta-analysis. Cardiovascular Therapeutics2015;33(4):242-6. [DOI: 10.1111/1755-5922.12133]">Xu 2015</a>). However, it is still thought that combination therapy (ablation and drugs together) is likely to be more effective than ablation alone. New trials such as <a href="./references#CD013765-bbs2-0083" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of Antiarrhythmic drugs Short-Term use after catheter ablation for Atrial Fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8.">Kaitani 2016</a> have since been conducted, and a new review was required. </p> <p>A recently updated Cochrane Review focused on the use of antiarrhythmic drugs after electrical cardioversion and concluded that the long‐term benefit of antiarrhythmic drugs is unclear (<a href="./references#CD013765-bbs2-0108" title="ValemboisL , AudureauE , TakedaA , JarzebowskiW , BelminJ , Lafuente‐LafuenteC . Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database of Systematic Reviews2019, Issue 9. Art. No: CD005049. [DOI: 10.1002/14651858.CD005049.pub5]">Valembois 2019</a>). Current guidelines from the National Institute for Health and Care Excellence (NICE) emphasise the need for expert opinion to guide the decision for ablation; however, there is no guidance on the use of antiarrythmic drugs with ablation (<a href="./references#CD013765-bbs2-0095" title="National Institute for Health and Care Excellence. Atrial fibrillation. www.nice.org.uk/guidance/ng196 (accessed 20 January 2021).">NICE 2019</a>). The 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society (AHA/ACC/HRS) guidelines and its 2019 focused update recommended ablation in people with AF, and that AF ablation is reasonable with symptomatic AF and heart failure in order to lower mortality rate and hospitalisation. However, there is no mention of antiarrhythmic drug use postablation (<a href="./references#CD013765-bbs2-0082" title="JanuaryCT , WannLS , CalkinsH , ChenLY , CigarroaJE , ClevelandJC . 2019 AHA/ACC/HRS focused update of the 2014 guideline for management of patients with atrial fibrillation. Journal of the American College of Cardiology2019;74(1):104-32.">January 2019b</a>). Given the high cost and risk of complications of a repeat ablation, and the toxicity and dangers of antiarrhythmic drugs, this is an important question to answer. </p> <p>The 2020 ESC guidelines recommend catheter ablation of AF in symptomatic patients with paroxysmal or persistent AF without major risk factors for recurrence (Class I recommendation with level A evidence) who have tried a Class I or III antiarrhythmic that failed or to which they were intolerant. Additionally, catheter ablation of AF should be considered as first‐line therapy in tachycardia‐induced cardiomyopathy independent of symptoms (Class I recommendation with level B evidence). The latest ESC guidelines discuss the need for data comparing different antiarrhythmic interventions in people with recurrent AF after catheter ablation, but lay out the need for further evidence (<a href="./references#CD013765-bbs2-0080" title="HindricksG , PotparaT , DagresN , ArbeloE , BaxJJ , Blomström-LundqvistC , et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. European Heart Journal2021;42(5):373–498. [DOI: 10.1093/eurheartj/ehaa612]">Hindricks 2020</a>; <a href="./references#CD013765-bbs2-0084" title="KirchhofP , BenussiS , KotechaD , AhlssonA , AtarD , CasadeiB , et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Revista Española de Cardiología [Spanish Journal of Cardiology]2017;70(1):50.">Kirchhof 2017</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013765-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013765-sec-0014"></div> <p>To assess the effects of oral Class I and III antiarrhythmic drugs versus control (standard medical therapy without Class I or III antiarrhythmics, or placebo) for maintaining sinus rhythm in people undergoing catheter ablation for atrial fibrillation (AF). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013765-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013765-sec-0015"></div> <section id="CD013765-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013765-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included all published, unpublished, and ongoing randomised controlled trials (RCTs) that were randomised at the level of the participant. We excluded cluster‐RCTs (as this method of randomisation will introduce dependence and thus require further analysis), cross‐over trials (due to the short follow‐up period and the long‐term effect of the drugs being used), and quasi‐randomised studies (due to the risk of selection bias). </p> </section> <section id="CD013765-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included adult participants (aged 18 years or older) of either sex who have had AF of any type or duration and had restoration of sinus rhythm with catheter ablation. For mixed populations, if only a subset met the inclusion criteria, we contacted the trial authors to obtain subgroup data. If we could not obtain the data for the subpopulation of interest, we included the study only if a minimum of 60% of the study population met the inclusion criteria, in which case we explored the impact of this decision in sensitivity analysis. We did not exclude any specific populations. </p> </section> <section id="CD013765-sec-0019"> <h4 class="title">Types of interventions</h4> <p> <ol id="CD013765-list-0002"> <li> <p>Combinations of any Class I and/or Class III antiarrhythmics versus control.</p> </li> <li> <p>Single Class I antiarrhythmics (flecainide, propafenone) versus control.</p> </li> <li> <p>Single Class III antiarrhythmics (amiodarone, dofetilide, dronedarone, sotalol) versus control. </p> </li> </ol> </p> <p>We defined control as standard medical therapy postablation not including Class I or III antiarrhythmics, or placebo with standard medical therapy postablation not including Class I or III antiarrhythmics. Non‐antiarrhythmic medications other than Class I or III antiarrhythmics were eligible as concomitant medications, provided they applied to all treatment arms. </p> <p>We defined standard medical therapy as rate‐controlling agents such as beta blockers, calcium channel blockers, and digoxin; novel anticoagulant agents and vitamin K antagonists; and other cardiac procedures such as coronary angioplasty, pacemaker implantation, and defibrillator implantation. </p> <p>Concomitant medications included but were not limited to angiotensin‐converting enzyme inhibitors, angiotensin receptor antagonists, statins, hypertension agents such as dihydropyridine calcium‐channel blockers, alpha blockers, diuretics, vasodilators such as hydralazine and minoxidil and centrally acting agents such as clonidine and methyldopa. </p> </section> <section id="CD013765-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We reported data from eligible studies for our prespecified outcomes, listed below. In cases of duplication, we considered the most relevant publication the primary source of data, and used duplicate publications as supplemental information. </p> <p>Given the difference in reporting and follow‐up of individual studies, and to avoid unit of analysis error, we presented our outcomes at several follow‐up periods (0 to 3 months, greater than 3 to 6 months, and greater than 6 months). Where possible, the longest available follow‐up was used. Our main follow‐up period of interest was greater than 3 to 6 months, given that 3 months is considered to be a 'blanking period' where ATa are not uncommon as the body is recovering from the ablation. </p> <section id="CD013765-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD013765-list-0003"> <li> <p>Participants with recurrence of any ATa (AF, atrial flutter, or atrial tachycardia) lasting greater than 30 seconds. </p> </li> <li> <p>Adverse events, considered separately as the following individual outcomes:</p> <ol id="CD013765-list-0004"> <li> <p>participants with a thromboembolic event (including transient ischaemic attack, ischaemic stroke, deep vein thrombosis, pulmonary embolism, and splanchnic vein thrombosis); </p> </li> <li> <p>participants with a myocardial infarction;</p> </li> <li> <p>participants with a new diagnosis of heart failure;</p> </li> <li> <p>participants who required hospitalisation one or more times for AF.</p> </li> </ol> </li> </ol> </p> </section> <section id="CD013765-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD013765-list-0005"> <li> <p>All‐cause mortality.</p> </li> <li> <p>The number of participants who required one or more repeat ablations.</p> </li> </ol> </p> </section> </section> </section> <section id="CD013765-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD013765-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We identified trials through systematic searches of the following bibliographic databases on 5 August 2022: </p> <p> <ol id="CD013765-list-0006"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library (Issue 8, 2022); </p> </li> <li> <p>MEDLINE ALL (Ovid, 1946 to 4 August 2022);</p> </li> <li> <p>Embase (Ovid, 1980 to 2022 week 30);</p> </li> <li> <p>Web of Science Core Collection (Clarivate Analytics, 1900 to 5 August 2022).</p> </li> </ol> </p> <p>We adapted the preliminary search strategy for MEDLINE (Ovid) for use in the other databases in 2020. We then updated these strategies in 2022 to include additional drug terms and a catheter ablation concept. The Cochrane sensitivity and precision maximising RCT filter was applied to MEDLINE (Ovid), and an adaption of this was applied to Web of Science (<a href="./references#CD013765-bbs2-0085" title="LefebvreC , GlanvilleJ , BriscoeS , LittlewoodA , MarshallC , Metzendorf M-I, et al. Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2.">Lefebvre 2021</a>). For Embase, the Cochrane RCT filter was applied (<a href="./references#CD013765-bbs2-0069" title="GlanvilleJ , FoxleeR , WisniewskiS , Noel-StorrA , EdwardsM , DooleyG . Translating the Cochrane EMBASE RCT filter from the Ovid interface to Embase.com: a case study. Health Information and Libraries Journal2019;36(3):264-77.">Glanville 2019</a>). </p> <p>We also conducted a search of ClinicalTrials.gov (<a href="http://www.ClinicalTrials.gov" target="_blank">www.clinicaltrials.gov</a>) and the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="http://(http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch</a>) for ongoing or unpublished trials on 5 August 2022. Our search strategies are shown in <a href="./appendices#CD013765-sec-0106">Appendix 1</a>. </p> <p>We searched all databases from their inception to the present, and imposed no restrictions on language of publication or publication status. We did not perform a separate search for adverse effects of interventions used for the treatment of AF (i.e. with Class I and III antiarrhythmics). We considered adverse effects as described in the included studies only. </p> </section> <section id="CD013765-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We checked reference lists of the included studies and any relevant systematic reviews identified for additional references to trials. We also examined any relevant retraction statements and errata for included studies. We contacted study authors for information on ongoing trials. </p> </section> </section> <section id="CD013765-sec-0026"> <h3 class="title" id="CD013765-sec-0026">Data collection and analysis</h3> <section id="CD013765-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Five review authors (JJHB, MWa, MWh, MA, CP) independently screened abstracts against the inclusion criteria, classifying them as eligible or not eligible. Each title was screened by at least two review authors, working independently, using Covidence software (<a href="./references#CD013765-bbs2-0058" title="Covidence. Version accessed 20 October 2020. Melbourne, Australia: Veritas Health Innovation, 2021. Available at covidence.org.">Covidence</a>). After retrieval of full‐text papers, five review authors (JJHB, MWa, MWh, MA, CP) independently screened the full texts and identified studies for inclusion and exclusion, with a minimum of two review authors working independently to screen each full text. Any disagreements were resolved through involvement of a third review author (JJHB, MA). We identified and excluded duplicates and collated multiple reports of the same study so that each study, rather than each report, was the unit of interest in the review. We recorded and reported the reasons for exclusion of full‐text reports. We completed a PRISMA flow diagram and 'Characteristics of excluded studies' table (<a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013319/references#CD013319-bbs2-0017" target="_blank">Liberati 2009</a>). We used Google Translate to translate non‐English manuscripts (<a href="./references#CD013765-bbs2-0071" title="Google Translate. Google, 2021. Available at translate.google.com.">Google Translate</a>). We expanded upon the reasons for exclusion of a small group of 'narrowly excluded trials', a subgroup of trials excluded following full‐text review that may have been eligible if not for the specific reasons detailed. </p> </section> <section id="CD013765-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>We used a data collection form that had been piloted on at least one study in the review. Four review authors (JJHB, MWa, MWh, CP) extracted the following study characteristics from the included studies. </p> <p> <ol id="CD013765-list-0007"> <li> <p>Methods: study design, total duration of study, number of study centres and location, study setting, and date of study. </p> </li> <li> <p>Participants: number (n) randomised, n lost to follow‐up/withdrawn, n analysed, mean age, age range, gender, inclusion criteria, and exclusion criteria. In addition, we collected data on left atrial size, percentage of paroxysmal and persistent AF, and presence of comorbidities (detailed in the <a href="#CD013765-sec-0009">Background</a> section and <a href="#CD013765-tbl-0004">Table 1</a>). </p> </li> <li> <p>Interventions: intervention, comparison, number of ablations per participant, concomitant medications, and excluded medications. </p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected, and time points reported for primary outcomes. </p> </li> <li> <p>Notes: funding for trial, and notable conflicts of interest of trial authors.</p> </li> </ol> </p> <div class="table" id="CD013765-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Participant characteristicsa </span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Age</b> </p> <p><b>(years)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sex</b> </p> <p><b>(% male)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mean AF duration</b> </p> <p><b>(months)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mean left atrial diameter</b> </p> <p><b>(cm)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of prior antiarrhythmics</b> </p> <p><b>(mean ±SD)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Previous AF ablations</b> </p> <p><b>(%)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hypertension</b> </p> <p><b>(%)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Diabetes</b> </p> <p><b>(%)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mean LVEF</b> </p> <p><b>(%)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013765-bbs2-0009" title="TurcoP , De SimoneA , La RoccaV , IulianoA , CapuanoV , AstaritaC , et al. Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation. Pacing and Clinical Electrophysiology2007;30:S112-5. "><b>Turco 2007</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.80</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.0</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. "><b>Roux 2009</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.60 ±1.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.5</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. "><b>Darkner 2014</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.15 ±0.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50.5</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. "><b>Hayashi 2014</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.80</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00 ±1.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.5</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. "><b>Lodziński 2014</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. "><b>Mohanty 2015</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.75</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54.5</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. "><b>Ad 2016</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.05</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54.8</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. "><b>Kaitani 2016</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.90</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.3</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. "><b>Tarasov 2017</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>( ‐ ) = not reported</p> <p>Abbreviations: AF: atrial fibrillation; LVEF: left ventricular ejection fraction; SD: standard deviation </p> <p><sup>a</sup>Abstracted or calculated total average from all relevant subgroups. </p> </div> </div> <p>Three of four review authors (JJHB, MWa, MWh, CP) independently extracted outcome data from each included study. Any disagreements were resolved by consensus or by involving a third review author (MA). One review author (JJHB) transferred data into the RevMan Web file (<a href="./references#CD013765-bbs2-0099" title="Review Manager Web (RevMan Web). Version 4.12.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web 2022</a>). We double‐checked that data had been entered correctly by comparing the data presented in the systematic review with the data extraction form. A second check of extracted data was performed by review authors MA, JJHB, MWa, and CP. </p> </section> <section id="CD013765-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two of four review authors (JJHB, MWa, MWh, CP) independently assessed risk of bias for each included study using the Cochrane risk of bias tool, as outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013765-bbs2-0076" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011a</a>). Any disagreements were resolved by discussion or by involving another review author (MA). We assessed risk of bias according to the following domains. </p> <p> <ol id="CD013765-list-0008"> <li> <p>Random sequence generation</p> </li> <li> <p>Allocation concealment</p> </li> <li> <p>Blinding of participants and personnel</p> </li> <li> <p>Blinding of outcome assessment</p> </li> <li> <p>Incomplete outcome data</p> </li> <li> <p>Selective outcome reporting</p> </li> <li> <p>Other bias</p> </li> </ol> </p> <p>We judged each study to be at low, high, or unclear risk of bias for each of the domains listed, and provided direct quotes from the study report along with justifications for our judgements in the risk of bias table. For a study to be considered at overall low risk of bias, it had to be low risk of bias for all domains, whilst studies were judged to be overall unclear or high risk of bias if they were assessed to be unclear or high risk within at least one domain, respectively. We were interested in quantifying the effect of assignment to the interventions at baseline, regardless of whether the interventions were received as intended (the ‘intention‐to‐treat' effect). When considering treatment effects, we took into account the risk of bias for the studies that contributed to that outcome. </p> </section> <section id="CD013765-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We used risk ratios to present our analyses of the following outcomes: recurrence of ATa, requirement for one or more repeat ablations, adverse events: myocardial infarction, and adverse events: requirement for one or more hospitalisations. For outcomes with very low event rates, defined as rates below 1%, we used the Peto one‐step odds ratio method, as this is considered the most powerful statistical method in this context, per Section 10.4.4.3 of the <i>Cochrane Handbook</i> (<a href="./references#CD013765-bbs2-0062" title="DeeksJJ , HigginsJP , AltmanDG , on behalf of the Cochrane Statistical Methods Group. Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Deeks 2022</a>). </p> </section> <section id="CD013765-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>In the case of multi‐arm trials, we used the data from the study arms for our prespecified comparisons (e.g. individual drugs versus placebo or no treatment) and excluded study arms that were irrelevant to the scope of this review. For studies that included placebo and no treatment as two different controls, we combined the control arms. </p> <p>For studies that reported more than one follow‐up time point, we analysed outcomes at the longest possible time of follow‐up as a separate comparison to avoid a unit of analysis error. </p> </section> <section id="CD013765-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators via email where missing data were considered to be a potential problem in order to maximise data inclusion and to verify key study characteristics. We planned to impute any missing data where reasonably possible, making explicit any assumptions used. We would include an assessment of the impact of imputation within our sensitivity analysis. </p> </section> <section id="CD013765-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We inspected forest plots visually to consider the direction and magnitude of effects and the degree of overlap between confidence intervals. We used the I<sup>2</sup> and Tau<sup>2</sup> statistics to measure heterogeneity amongst the trials in each analysis. We acknowledge that there is substantial uncertainty in the I<sup>2</sup> value when there are only a small number of studies. We also considered the P value from the Chi<sup>2</sup> test. We reported the clinical characteristics of the included studies including inclusion and exclusion criteria to help guide our clinical assessment of heterogeneity. </p> <p>When we identified substantial heterogeneity we reported this. Moreover, we planned to carry out subgroup analyses for all outcomes. We considered heterogeneity as substantial if there was a low P value (less than 0.1) in the Chi<sup>2</sup> test for heterogeneity, or if Tau<sup>2</sup> was greater than zero. As strict thresholds for interpreting I<sup>2</sup> are not recommended, we followed the rough guide outlined in Section 10.10.2 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013765-bbs2-0062" title="DeeksJJ , HigginsJP , AltmanDG , on behalf of the Cochrane Statistical Methods Group. Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Deeks 2022</a>; <a href="./references#CD013765-bbs2-0078" title="HigginsJP , AltmanDG , SterneJAC , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017. In: Available from training.cochrane.org/handbook/archive/v5.2. Cochrane, 2017.">Higgins 2017</a>): </p> <p> <ol id="CD013765-list-0009"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100%: probable considerable heterogeneity.</p> </li> </ol> </p> <p>We only pooled studies if they were considered similar, without substantial heterogeneity.</p> </section> <section id="CD013765-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>For analyses that included 10 or more studies, we planned to create a funnel plot to explore potential publication bias and to perform a formal statistical test for asymmetry (<a href="./references#CD013765-bbs2-0067" title="EggerM , SmithGD , SchneiderM , ChristophM . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315:629.">Egger 1997</a>). In the case of a small number of included studies, the ability to detect publication bias is largely diminished, and it is difficult to exclude the presence of publication bias. </p> </section> <section id="CD013765-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We undertook meta‐analyses only where this was meaningful, that is where the treatments, participants, and the underlying clinical question were similar enough for pooling to make sense, and in the absence of substantial heterogeneity (&gt; 50%). We carried out statistical analysis using RevMan Web (<a href="./references#CD013765-bbs2-0099" title="Review Manager Web (RevMan Web). Version 4.12.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web 2022</a>). Due to clinical heterogeneity across trials with AF ablation, differences in comorbidities, differences in medication dose, and the addition of co‐interventions, we used a random‐effects model for our meta‐analysis. We looked at the random‐effects summary as the average range of possible treatment effects. We presented the average treatment effect with a 95% confidence interval. We included all eligible studies regardless of their risk of bias, and carried out sensitivity analysis to determine whether risk of bias could affect our conclusions. Where results were statistically significant within the summary of findings tables, the number needed to treat for an additional beneficial outcome (NNTB) is provided, calculated using the assumed comparator risk (ACR) and the effect estimate, per Section 15.4.4 of the <i>Cochrane Handbook</i> (<a href="./references#CD013765-bbs2-0103" title="SchünemannHJ , VistGE , HigginsJP , SantessoN , DeeksJJ , GlasziouP , et al, on behalf of the Cochrane GRADEing Methods Group. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated August 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Schünemann 2019</a>). </p> <p>We reported baseline characteristics as weighted means where possible, with standard deviations (SD) produced from the mean from each relevant study. Where medians were reported, the average is accompanied by an interquartile range (IQR). </p> </section> <section id="CD013765-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to carry out subgroup analyses for all outcomes, and the following factors, but only for &gt; 3 to 6 months (our primary time point of interest). </p> <p> <ol id="CD013765-list-0010"> <li> <p>Participants undergoing their first ablation versus those who have undergone successive ablations (to explore whether drugs are more or less successful in people who have undergone previous unsuccessful ablations). This subgroup analysis applied to all three planned comparisons. </p> </li> <li> <p>Each individual drug (flecainide, propafenone, amiodarone, dofetilide, dronedarone, and sotalol) versus control. This subgroup analysis only applied to comparisons 1 and 2 (<a href="#CD013765-sec-0019">Types of interventions</a>). </p> </li> </ol> </p> </section> <section id="CD013765-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We carried out the following sensitivity analyses on all outcomes where feasible.</p> <p> <ol id="CD013765-list-0011"> <li> <p>Only including studies with low overall risk of bias. We considered a study to be at low risk of bias for this analysis if it met the criteria for low risk of bias in the following domains: random sequence generation, allocation concealment, and incomplete outcome data. </p> </li> <li> <p>Only including studies without missing data.</p> </li> </ol> </p> <p>As recommended in the <i>Cochrane Handbook</i>, we carried out further sensitivity analysis on i) eligibility criteria, ii) data analysis, and iii) analysis methods, and assessed whether the result could impact our conclusions (<a href="./references#CD013765-bbs2-0061" title="DeeksJJ , HigginsJP , AltmanDG , on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Deeks 2011</a>), as follows. </p> <p> <ol id="CD013765-list-0012"> <li> <p>Risk of bias (including only studies at low risk of bias, and only studies at low and unclear risk of bias) </p> </li> <li> <p>Removal of surgical ablation as the minority ablation method used (see <a href="#CD013765-tbl-0005">Table 2</a>). </p> </li> <li> <p>Addition of narrowly excluded trials, defined as a subgroup of trials excluded following full‐text review that may have been eligible if not for the specific reasons detailed. </p> </li> <li> <p>Impact of restriction to trials mainly including participants with paroxysmal AF.</p> </li> <li> <p>Effect of using random‐effects analysis with odds ratio as opposed to risk ratio.</p> </li> </ol> </p> <div class="table" id="CD013765-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Ablation approach and strategy</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Trial</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Approach</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ablation strategy</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. "><b>Ad 2016</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgical ablation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cox maze III/IV lesion set, utilised in all but 1 participant</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. "><b>Darkner 2014</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percutaneous ablation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary vein isolation/wide antral circumferential ablation</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. "><b>Hayashi 2014</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percutaneous ablation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary vein isolation</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. "><b>Kaitani 2016</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percutaneous ablation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary vein isolation/wide antral circumferential ablation</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. "><b>Lodziński 2014</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percutaneous ablation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary vein isolation</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. "><b>Mohanty 2015</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percutaneous ablation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary vein antral isolation + posterior wall isolation + defragmentation + extra pulmonary vein triggers </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. "><b>Roux 2009</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percutaneous ablation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary vein isolation + extra pulmonary vein triggers</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. "><b>Tarasov 2017</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percutaneous ablation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary vein ostial isolation</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013765-bbs2-0009" title="TurcoP , De SimoneA , La RoccaV , IulianoA , CapuanoV , AstaritaC , et al. Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation. Pacing and Clinical Electrophysiology2007;30:S112-5. "><b>Turco 2007</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percutaneous ablation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary vein isolation + mitral isthmus + cavo‐tricuspid isthmus</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD013765-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created separate summary of findings tables for each of our comparisons, as follows.</p> <p> <ol id="CD013765-list-0013"> <li> <p>Combinations of any Class I and/or Class III antiarrhythmics versus control.</p> </li> <li> <p>Single Class I antiarrhythmics (flecainide, propafenone) versus control.</p> </li> <li> <p>Single Class III antiarrhythmics (amiodarone, dofetilide, dronedarone, sotalol) versus control. </p> </li> </ol> </p> <p>The summary of findings tables include the outcomes listed in <a href="#CD013765-sec-0020">Types of outcome measures</a>. The summary of findings tables cover all outcomes for the follow‐up periods of 0 to 3 months, &gt; 3 to 6 months, and &gt; 6 months. The &gt; 3 to 6 months follow‐up period immediately following the blanking period was our primary time point of interest. </p> <p>We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the certainty of the body of evidence as it relates to the studies which contribute data to the meta‐analyses for the prespecified outcomes. We used the methods and recommendations described in Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013765-bbs2-0102" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Schünemann 2017</a>), employing GRADEpro GDT software (<a href="./references#CD013765-bbs2-0072" title="GRADEpro GDT. Version accessed 23 June 2021. Hamilton (ON): McMaster University (developed by Evidence Prime), 2013. Available at gradepro.org.">GRADEpro GDT</a>). We used the overall risk of bias judgement from the Cochrane risk of bias tool as part of GRADE assessment for each outcome. We justified all decisions to downgrade the certainty of the evidence using footnotes, and added comments to aid the reader's understanding of the review where necessary. </p> <p>To investigate imprecision, we calculated the optimal information size (OIS) using default type I error probability and power (α 0.05, power 0.80), by comparing proportions of two independent samples, as recommended in the GRADE Handbook (<a href="./references#CD013765-bbs2-0101" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.">Schünemann 2013</a>). </p> <p>Two of three review authors (JJHB, MWa, MWh), working independently, judged the certainty of the evidence, with any disagreements resolved by discussion or by involving a third review author (MA). Judgements were justified, documented, and incorporated into the reporting of results for each outcome. We extracted study data, formatted our comparisons in data tables, and prepared summary of findings tables before writing the results and conclusions of our review. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013765-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013765-sec-0039"></div> <section id="CD013765-sec-0040"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD013765-sec-0115" title="">Characteristics of included studies</a>. </p> <section id="CD013765-sec-0041"> <h4 class="title">Results of the search</h4> <p>Our search identified 8002 citations; following deduplication, 4682 citations were reduced to 59 potentially relevant articles (<a href="#CD013765-fig-0001">Figure 1</a>), from which we identified nine eligible RCTs for inclusion. There were three additional published duplicates or supplementary manuscripts of <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a> (AMIO‐CAT) (<a href="./references#CD013765-bbs2-0059" title="DarknerS , HansenJ , PehrsonS , JohannessenA , SvendsenJH . Effect of arrhythmia burden and arrhythmia-related events on quality of life in patients undergoing ablation for atrial fibrillation: a substudy of the AMIO-CAT trial. Europace2015;17 Suppl 3:iii111.">Darkner 2015</a>; <a href="./references#CD013765-bbs2-0060" title="DarknerS , GoetzeJP , ChenX , HenningsenK , PehrsonS , SvendsenJH . Natriuretic propeptides as markers of atrial fibrillation burden and recurrence (from the AMIO-CAT trial). American Journal of Cardiology2017;120(8):1309-15.">Darkner 2017</a>; <a href="./references#CD013765-bbs2-0065" title="DiederichsenSZ , DarknerS , ChenX , JohannesenA , PehrsonS , HansenJ , et al. Short-term amiodarone treatment for atrial fibrillation after catheter ablation induces a transient thyroid dysfunction: results from the placebo-controlled, randomized AMIO-CAT trial. European Journal of Internal Medicine2016;33(1879-0828 (Electronic)):36-41.">Diederichsen 2016</a>); two of <a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. ">Mohanty 2015</a> (SPECULATE) (<a href="./references#CD013765-bbs2-0063" title="Di BiaseL , SantangelliP , MohantyP , BurkhardtJD , SanchezJE , HortonR , et al. Abstract 14381: Preliminary results from the SPECULATE randomized study: effect of amiodarone on the procedure outcome in long-standing persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation. Circulation2011;124(Suppl 21):A14381.">Di Biase 2011</a>; <a href="./references#CD013765-bbs2-0064" title="Di BiaseL , SantangeliP , MohantyP , BurkhardtJD , SanchezJE , LakkireddyD , et al. In patients undergoing ablation of long standing persistent AF amiodarone increases the AF termination during ablation but reduces the long term success: preliminary results from the speculate study. European Heart Journal2012;33:230.">Di Biase 2012</a>) and <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a> (<a href="./references#CD013765-bbs2-0106" title="TarasovAV , ReynbakhO , DavtyanKV , MartsevichSY . 1670 Antiarrhythmic drugs in blanking period after catheter ablation of atrial fibrillation do not change effectiveness of the procedure but add clinical benefit. Europace2017;19(Suppl 3):iii356.">Tarasov 2017a</a>; <a href="./references#CD013765-bbs2-0107" title="TarasovAV , ReynbakhO , DavtyanKV , MartsevichSY . P2705 Comparison of antiarrhythmic drugs clinical effect during early post procedural period after atrial fibrillation ablation. European Heart Journal2017;38(Suppl 1):ehx502.P2705.">Tarasov 2017b</a>); and one at six‐month follow‐up of <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a> (5A study) (<a href="./references#CD013765-bbs2-0087" title="Leong-SitP , Roux J-F, ZadoE , CallansDJ , GarciaF , LinD , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation: Arrhythmia and Electrophysiology2011;4(1):11-4.">Leong‐Sit 2011</a>). Search strategies are shown in <a href="./appendices#CD013765-sec-0106">Appendix 1</a>. We identified two eligible trials with a multi‐arm design (<a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. ">Lodziński 2014</a>; <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>); it was possible to combine the arms of <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a> as necessary, whereas one arm of <a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. ">Lodziński 2014</a> involving participants taking "previous antiarrhythmics" was excluded from analysis. </p> <div class="figure" id="CD013765-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA flow diagram." data-id="CD013765-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA flow diagram.</p> </div> </div> </div> <p>We planned to carry out subgroup analyses for all outcomes, but this was not feasible due to an insufficient number of pooled studies. No missing data were identified. </p> </section> <section id="CD013765-sec-0042"> <h4 class="title">Included studies</h4> <section id="CD013765-sec-0043"> <h5 class="title">Participants and ablation procedures</h5> <p>Study‐level baseline participant characteristics are shown in <a href="#CD013765-tbl-0004">Table 1</a>. </p> <p>We included nine RCTs involving a total of 3269 participants randomised to receive either a Class I or III antiarrhythmic (or both) or placebo/standard care after ablation for AF (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>; <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>; <a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. ">Lodziński 2014</a>; <a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. ">Mohanty 2015</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>; <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>; <a href="./references#CD013765-bbs2-0009" title="TurcoP , De SimoneA , La RoccaV , IulianoA , CapuanoV , AstaritaC , et al. Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation. Pacing and Clinical Electrophysiology2007;30:S112-5. ">Turco 2007</a>). Each included RCT had a reasonable sample size, with a median of 126 ±109 to 232 participants (range 97 to 2044), and follow‐up durations of mean 27 ±11.2 months (range 13 to 48 months). Trials recruited from six different countries, with three trials recruiting from the USA (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>; <a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. ">Mohanty 2015</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>), one from Italy (<a href="./references#CD013765-bbs2-0009" title="TurcoP , De SimoneA , La RoccaV , IulianoA , CapuanoV , AstaritaC , et al. Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation. Pacing and Clinical Electrophysiology2007;30:S112-5. ">Turco 2007</a>), two from Japan (<a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>), one from Denmark (<a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>), one from Poland (<a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. ">Lodziński 2014</a>), and one from Russia (<a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>). The mean age of participants was 59.3 ±5.14 years, and 71.0% ±7.12% of participants were male. The proportion of participants with paroxysmal AF and persistent AF was 72.9% ±30.0% and 27.4% ±30.3%, respectively. Two studies only included paroxysmal AF (<a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>; <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>). Participants in the included trials had a mean AF duration of 53.2 ±25.7 months, ranging from a trial average of 16.5 months to 79.5 months, and the mean left atrial diameter was 4.09 ±0.43 cm (trial mean range 3.8 cm to 5.1 cm). Number of prior antiarrhythmics and previous ablations for AF were generally poorly reported. Three studies reported an average of 1.22 previous antiarrhythmics amongst their included participants (<a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>), and <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a> reported that 59.4% of their participants had been taking at least one ineffective antiarrhythmic before start of the trial. Four studies commented on history of previous AF ablation, with two studies reporting that all of their participants were receiving their first ablation (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>; <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>), and two studies including an average of 27.1% of participants who were receiving a second ablation (<a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>). Regarding comorbidities, 50.4% ±8.20% of participants had hypertension; 11.8% ±3.42% had diabetes; and the mean left ventricular ejection fraction was 62.9% ±6.31%. </p> <p>The majority of trials implemented percutaneous catheter ablation (<a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>; <a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. ">Lodziński 2014</a>; <a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. ">Mohanty 2015</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>; <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>; <a href="./references#CD013765-bbs2-0009" title="TurcoP , De SimoneA , La RoccaV , IulianoA , CapuanoV , AstaritaC , et al. Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation. Pacing and Clinical Electrophysiology2007;30:S112-5. ">Turco 2007</a>), most of which were radiofrequency ablations (<a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. ">Lodziński 2014</a>; <a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. ">Mohanty 2015</a>; <a href="./references#CD013765-bbs2-0009" title="TurcoP , De SimoneA , La RoccaV , IulianoA , CapuanoV , AstaritaC , et al. Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation. Pacing and Clinical Electrophysiology2007;30:S112-5. ">Turco 2007</a>). One trial used surgical ablation (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>). The majority of trials implemented an ablation strategy that involved the pulmonary veins in order to restore sinus rhythm. Specific approaches and strategies of the included trials are summarised in <a href="#CD013765-tbl-0005">Table 2</a>. </p> </section> <section id="CD013765-sec-0044"> <h5 class="title">Intervention and comparator</h5> <p>One trial exclusively used Class I antiarrhythmics (flecainide) (<a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>), and four trials exclusively used Class III antiarrhythmics (<a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. ">Lodziński 2014</a>), of which three used amiodarone (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>; <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. ">Mohanty 2015</a>). Three trials used a combination of Class I and/or III antiarrhythmics (<a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>; <a href="./references#CD013765-bbs2-0009" title="TurcoP , De SimoneA , La RoccaV , IulianoA , CapuanoV , AstaritaC , et al. Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation. Pacing and Clinical Electrophysiology2007;30:S112-5. ">Turco 2007</a>), and one trial reported subgroups of both Class I and II antiarrhythmics (<a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>). Doses of Class I and III antiarrhythmics were clinically appropriate where reported; three trials did not specify antiarrhythmic doses (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>; <a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. ">Lodziński 2014</a>; <a href="./references#CD013765-bbs2-0009" title="TurcoP , De SimoneA , La RoccaV , IulianoA , CapuanoV , AstaritaC , et al. Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation. Pacing and Clinical Electrophysiology2007;30:S112-5. ">Turco 2007</a>). Before the initiation of each trial, a run‐in period of median of 3 ±1 to 3 months was used (range 0.25 to 4 months), with <a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. ">Lodziński 2014</a> using a run‐in period of 7 days. Antiarrhythmics were used for a blanking period of median 8 ±5.25 to 12.2 weeks; <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a> reported having titrated down the dose of amiodarone over the duration of their blanking period. <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a> used flecainide throughout the duration of follow‐up. Two trials did not specify the duration of postablation antiarrhythmic therapy (<a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. ">Lodziński 2014</a>; <a href="./references#CD013765-bbs2-0009" title="TurcoP , De SimoneA , La RoccaV , IulianoA , CapuanoV , AstaritaC , et al. Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation. Pacing and Clinical Electrophysiology2007;30:S112-5. ">Turco 2007</a>). In most included studies, the comparator was ablation alone, without antiarrhythmics (<a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. ">Lodziński 2014</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>; <a href="./references#CD013765-bbs2-0009" title="TurcoP , De SimoneA , La RoccaV , IulianoA , CapuanoV , AstaritaC , et al. Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation. Pacing and Clinical Electrophysiology2007;30:S112-5. ">Turco 2007</a>), no amiodarone (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>; <a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. ">Mohanty 2015</a>), non‐Class I or III antiarrhythmics (<a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>), or the studies did not specify beyond ‘control’ (<a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>; <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>). </p> </section> <section id="CD013765-sec-0045"> <h5 class="title">Outcomes</h5> <p>In nine included trials, data were provided on our primary outcome of ATa recurrence. Data for this outcome came from electrocardiogram (ECG) recordings taken at regular intervals using an ECG event recorder or transtelephonic ECG (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>; <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>; <a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. ">Mohanty 2015</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>; <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>; <a href="./references#CD013765-bbs2-0009" title="TurcoP , De SimoneA , La RoccaV , IulianoA , CapuanoV , AstaritaC , et al. Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation. Pacing and Clinical Electrophysiology2007;30:S112-5. ">Turco 2007</a>), ambulatory ECG monitoring (<a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>; <a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. ">Lodziński 2014</a>; <a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. ">Mohanty 2015</a>; <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>; <a href="./references#CD013765-bbs2-0009" title="TurcoP , De SimoneA , La RoccaV , IulianoA , CapuanoV , AstaritaC , et al. Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation. Pacing and Clinical Electrophysiology2007;30:S112-5. ">Turco 2007</a>), and/or 12‐lead ECGs (<a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>; <a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. ">Mohanty 2015</a>; <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>; <a href="./references#CD013765-bbs2-0009" title="TurcoP , De SimoneA , La RoccaV , IulianoA , CapuanoV , AstaritaC , et al. Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation. Pacing and Clinical Electrophysiology2007;30:S112-5. ">Turco 2007</a>). Most trials did not specify the duration of reported recurrences of ATa (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>; <a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. ">Lodziński 2014</a>; <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>; <a href="./references#CD013765-bbs2-0009" title="TurcoP , De SimoneA , La RoccaV , IulianoA , CapuanoV , AstaritaC , et al. Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation. Pacing and Clinical Electrophysiology2007;30:S112-5. ">Turco 2007</a>); those that did reported complete freedom (<a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. ">Mohanty 2015</a>), ATa lasting &gt; 30 s (<a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>), or ATa lasting &gt; 24 h (<a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>). Regarding secondary outcomes, three trials reported all‐cause mortality (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>; <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>); four trials reported participants requiring one or more repeat ablations (<a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>; <a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. ">Mohanty 2015</a>; <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>); and six trials reported adverse events of interest (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>; <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>; <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>). </p> </section> <section id="CD013765-sec-0046"> <h5 class="title">Other characteristics</h5> <p>Five studies reported power calculations with a minimum median size of n = 182 ±124 to 182 (range 124 to 1840) (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>; <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>). Five studies did not report industry funding (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>; <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>); three studies specifically stated that they received no industry funding (<a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>); and one study reported having received industry funding (<a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>). </p> <p><a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. ">Lodziński 2014</a> had a high attrition rate divided by intervention, thus we included assessment of this factor in sensitivity analysis. </p> </section> </section> <section id="CD013765-sec-0047"> <h4 class="title">Excluded studies</h4> <p>See <a href="./references#CD013765-sec-0116" title="">Characteristics of excluded studies</a>. </p> <p>The reason for exclusion of most studies excluded at the full‐text stage was wrong design (n = 23 of 44 excluded; see <a href="#CD013765-fig-0001">Figure 1</a>). There are five noteworthy excluded studies that narrowly missed inclusion (<a href="./references#CD013765-bbs2-0010" title="BrignoleM , MenozziC , GaspariniM , BongiorniMG , BottoGL , OmettoR , et al, on behalf of the PAF 2 Study Investigators. An evaluation of the strategy of maintenance of sinus rhythm by antiarrhythmic drug therapy after ablation and pacing therapy in patients with paroxysmal atrial fibrillation. European Heart Journal2002;23:892-900. ">Brignole 2002</a>; <a href="./references#CD013765-bbs2-0066" title="DuytschaeverM , DemolderA , PhlipsT , SarkozyA , El HaddadM , TaghjiP , et al. PulmOnary vein isolation With vs. without continued antiarrhythmic Drug trEatment in subjects with Recurrent Atrial Fibrillation (POWDER AF): results from a multicentre randomized trial. European Heart Journal2018;39(16):1429-37.">Duytschaever 2018</a>; <a href="./references#CD013765-bbs2-0043" title="StabileG , BertagliaE , SenatoreG , De SimoneA , ZoppoF , DonniciG , et al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation for the Cure of Atrial Fibrillation Study). European Heart Journal2006;27(2):216-21. ">Stabile 2006</a>; <a href="./references#CD013765-bbs2-0048" title="WangL , LiuQ , MaX . Impact of amiodarone on cardiac structural function and MMP-2 and TIMP-2 levels in atrial fibrillation radiofrequency ablation. International Journal of Clinical and Experimental Medicine2019;12(4):4287-93. ">Wang 2019</a>; <a href="./references#CD013765-bbs2-0051" title="WuG , JiangH , Huang C-X, YangB , HuangH , Wang Y-L, et al. Effects of antiarrhythmic drug use on atrial fibrillation recurrence in atrial fibrillation patients post circumferential pulmonary vein ablation. Zhonghua Xin Xue Guan Bing Za Zhi [Chinese Journal of Cardiology]2008;36(7):623-6. ">Wu 2008</a>). <a href="./references#CD013765-bbs2-0042" title="StabileG , De Simone, TurcoP , La RoccaV , NocerinoP , AstaritaC , et al. Response to flecainide infusion predicts long-term success of hybrid pharmacologic and ablation therapy in patients with atrial fibrillation. Journal of the American College of Cardiology2001;37(6):1639-44. ">Stabile 2001</a> was excluded because although it reported freedom from AF and atrial flutter recurrence at 15 months, this subgroup did not represent &gt; 60% of the total study size; instead, this study was included in sensitivity analysis. <a href="./references#CD013765-bbs2-0048" title="WangL , LiuQ , MaX . Impact of amiodarone on cardiac structural function and MMP-2 and TIMP-2 levels in atrial fibrillation radiofrequency ablation. International Journal of Clinical and Experimental Medicine2019;12(4):4287-93. ">Wang 2019</a> provided no data that could be used in any of our primary and secondary outcomes, and was thus excluded; we contacted the authors to enquire about potential unpublished data, but did not receive a response. <a href="./references#CD013765-bbs2-0066" title="DuytschaeverM , DemolderA , PhlipsT , SarkozyA , El HaddadM , TaghjiP , et al. PulmOnary vein isolation With vs. without continued antiarrhythmic Drug trEatment in subjects with Recurrent Atrial Fibrillation (POWDER AF): results from a multicentre randomized trial. European Heart Journal2018;39(16):1429-37.">Duytschaever 2018</a> included Class I or III antiarrhythmics in both the control and intervention arms. <a href="./references#CD013765-bbs2-0051" title="WuG , JiangH , Huang C-X, YangB , HuangH , Wang Y-L, et al. Effects of antiarrhythmic drug use on atrial fibrillation recurrence in atrial fibrillation patients post circumferential pulmonary vein ablation. Zhonghua Xin Xue Guan Bing Za Zhi [Chinese Journal of Cardiology]2008;36(7):623-6. ">Wu 2008</a> was excluded because we were unable to confirm if the antiarrhythmics used were Class I or III. We excluded <a href="./references#CD013765-bbs2-0010" title="BrignoleM , MenozziC , GaspariniM , BongiorniMG , BottoGL , OmettoR , et al, on behalf of the PAF 2 Study Investigators. An evaluation of the strategy of maintenance of sinus rhythm by antiarrhythmic drug therapy after ablation and pacing therapy in patients with paroxysmal atrial fibrillation. European Heart Journal2002;23:892-900. ">Brignole 2002</a> because we sought studies that investigated maintenance of sinus rhythm following ablation, and this study used atrioventricular nodal ablation, thus following ablation participants would not be in sinus rhythm. </p> <p><a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a> describes the potential for cross‐over but was principally of parallel design; we included this study and used data taken before any cross‐over. </p> </section> </section> <section id="CD013765-sec-0048"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="./references#CD013765-sec-0115" title="">Characteristics of included studies</a>, <a href="#CD013765-fig-0002">Figure 2</a>, and <a href="#CD013765-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD013765-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013765-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD013765-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013765-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD013765-sec-0049"> <h4 class="title">Allocation</h4> <p>Five trials explicitly reported adequate random sequence generation (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>; <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>; <a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. ">Mohanty 2015</a>; <a href="./references#CD013765-bbs2-0009" title="TurcoP , De SimoneA , La RoccaV , IulianoA , CapuanoV , AstaritaC , et al. Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation. Pacing and Clinical Electrophysiology2007;30:S112-5. ">Turco 2007</a>), and three trials described using randomisation and implied adequate sequence generation (<a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. ">Lodziński 2014</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>; <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>). <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a> describe an error in their randomisation program, which they attempted to mitigate by re‐allocating individuals towards imbalances. </p> <p>Three studies used adequate allocation concealment (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>; <a href="./references#CD013765-bbs2-0009" title="TurcoP , De SimoneA , La RoccaV , IulianoA , CapuanoV , AstaritaC , et al. Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation. Pacing and Clinical Electrophysiology2007;30:S112-5. ">Turco 2007</a>), and three studies likely used adequate allocation concealment (<a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>). Insufficient information regarding allocation concealment was provided in three studies, leading to a judgement of unclear risk of bias (<a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. ">Lodziński 2014</a>; <a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. ">Mohanty 2015</a>; <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>). </p> </section> <section id="CD013765-sec-0050"> <h4 class="title">Blinding</h4> <p>We considered <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>, a double‐blind, placebo‐controlled trial, to be at low risk of performance bias. For three trials, information was insufficient to assess whether participants and personnel could have been aware of the allocation; we assessed these studies as at unclear risk performance bias (<a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. ">Lodziński 2014</a>; <a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. ">Mohanty 2015</a>; <a href="./references#CD013765-bbs2-0009" title="TurcoP , De SimoneA , La RoccaV , IulianoA , CapuanoV , AstaritaC , et al. Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation. Pacing and Clinical Electrophysiology2007;30:S112-5. ">Turco 2007</a>). Five trials were clearly non‐blinded and were therefore assessed as at high risk of performance bias due to the possibility that this may have introduced differences between randomised groups other than the intervention being evaluated (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>; <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>; <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>). </p> <p>We also considered <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a> to be at low risk for detection bias, as the assessors in this trial were blinded. Most included trials provided insufficient information to judge blinding of outcome assessment and were thus considered to be at unclear risk of detection bias (<a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>; <a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. ">Lodziński 2014</a>; <a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. ">Mohanty 2015</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>; <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>; <a href="./references#CD013765-bbs2-0009" title="TurcoP , De SimoneA , La RoccaV , IulianoA , CapuanoV , AstaritaC , et al. Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation. Pacing and Clinical Electrophysiology2007;30:S112-5. ">Turco 2007</a>). <a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a> and <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a> did not blind outcome assessors and were thus considered to be at high risk of detection bias, as the lack of blinding could have led to changes to recorded outcomes. </p> </section> <section id="CD013765-sec-0051"> <h4 class="title">Incomplete outcome data</h4> <p>All trials but one had low rates of loss to follow‐up (median 0.64% ±0.86% (range 0% to 2.36%)), without differential group loss (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>; <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>; <a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. ">Mohanty 2015</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>; <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>; <a href="./references#CD013765-bbs2-0009" title="TurcoP , De SimoneA , La RoccaV , IulianoA , CapuanoV , AstaritaC , et al. Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation. Pacing and Clinical Electrophysiology2007;30:S112-5. ">Turco 2007</a>). </p> <p><a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a> implemented a per‐protocol analysis by excluding participants who were lost to follow‐up from analysis, and was thus considered at high risk of attrition bias. </p> <p><a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. ">Lodziński 2014</a> had a loss to follow‐up rate of 18.6% at 2‐month follow‐up and 34.8% at a mean of 55‐month follow‐up. It was not possible to ascertain whether there was differential loss between groups, and no sensitivity analyses were reported. We therefore judged this study to be at unclear risk of attrition bias. </p> </section> <section id="CD013765-sec-0052"> <h4 class="title">Selective reporting</h4> <p>In all included trials, the method of measuring the outcomes of interest was appropriate, and measurement of each outcome did not differ between groups. However, as previously stated, outcome assessors were aware of the intervention in most included trials (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>; <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>; <a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. ">Lodziński 2014</a>; <a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. ">Mohanty 2015</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>; <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>); this was not mentioned in one trial (<a href="./references#CD013765-bbs2-0009" title="TurcoP , De SimoneA , La RoccaV , IulianoA , CapuanoV , AstaritaC , et al. Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation. Pacing and Clinical Electrophysiology2007;30:S112-5. ">Turco 2007</a>); and outcome assessors were presumably blinded in the remaining trial, which was described as "double‐blind" but not further specified (<a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>). Due to this, all included studies were judged to be low risk of bias in measurement of the outcomes of interest. </p> <p>Five trials analysed results in accordance with a prespecified plan (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>; <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>; <a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. ">Mohanty 2015</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>), reporting results in the final published manuscript as set out in a prespecified protocol (a priori on ClinicalTrials.gov). Three trials likely used a prespecified plan (<a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>; <a href="./references#CD013765-bbs2-0009" title="TurcoP , De SimoneA , La RoccaV , IulianoA , CapuanoV , AstaritaC , et al. Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation. Pacing and Clinical Electrophysiology2007;30:S112-5. ">Turco 2007</a>), and one trial described deviating from protocol in recording of their results (<a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. ">Lodziński 2014</a>). <a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. ">Lodziński 2014</a> describes how most of the centres that recruited participants used differing protocols to record results, and therefore results were “divided into groups” "to make them comparable”. It is thus implied that these results were analysed using a plan produced after collection of results. The included studies do not appear to have selected from multiple outcome measurements. <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a> appeared to have potentially performed several analyses of the data to produce three similar presentations of the data, although these duplicates were all comparable. We therefore considered eight trials to be at low risk of reporting bias (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>; <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>; <a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. ">Mohanty 2015</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>; <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>; <a href="./references#CD013765-bbs2-0009" title="TurcoP , De SimoneA , La RoccaV , IulianoA , CapuanoV , AstaritaC , et al. Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation. Pacing and Clinical Electrophysiology2007;30:S112-5. ">Turco 2007</a>), and <a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. ">Lodziński 2014</a> to be at unclear risk of reporting bias. </p> </section> <section id="CD013765-sec-0053"> <h4 class="title">Other potential sources of bias</h4> <p>All trials but two provided baseline characteristics evidence supporting the adequacy of their randomisation procedures. <a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. ">Lodziński 2014</a> provided neither information nor comment that would enable the comparison of characteristics between intervention arms, and was thus considered to be unclear risk of other bias. As mentioned above, <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a> attempted to mitigate an error in their randomisation program by re‐allocating individuals towards imbalances. However, there were residual significant differences in age, sex, body weight, some comorbidities, and aspects of the ablation procedure that would not be consistent with chance given the large participant number; we thus judged <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a> to be at high risk of other bias. </p> <p>It is also worth noting that <a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. ">Lodziński 2014</a> had a particularly short run‐in of seven days. If participants had been taking Class I or III antiarrhythmics with long half‐lives, such as amiodarone, then this could have affected the results, especially as there is no mention of whether participants were on antiarrhythmics before study inclusion. </p> </section> </section> <section id="CD013765-sec-0054"> <h3 class="title" id="CD013765-sec-0054">Effects of interventions</h3> <p>See: <a href="./full#CD013765-tbl-0001"><b>Summary of findings 1</b> Class I and/or III antiarrhythmics versus control for maintaining sinus rhythm after catheter ablation of atrial fibrillation</a>; <a href="./full#CD013765-tbl-0002"><b>Summary of findings 2</b> Class I antiarrhythmics versus control for maintaining sinus rhythm after catheter ablation of atrial fibrillation</a>; <a href="./full#CD013765-tbl-0003"><b>Summary of findings 3</b> Class III antiarrhythmics versus control for maintaining sinus rhythm after catheter ablation of atrial fibrillation</a> </p> <p>The vast majority of available data were eligible for inclusion in our meta‐analyses (see analyses below). </p> <section id="CD013765-sec-0055"> <h4 class="title">Class I and/or III versus control</h4> <p>See <a href="./full#CD013765-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD013765-sec-0056"> <h5 class="title">Recurrence of atrial tachyarrhythmias</h5> <p>Nine included trials provided data on recurrence of ATa (3269 participants) (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>; <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>; <a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. ">Lodziński 2014</a>; <a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. ">Mohanty 2015</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>; <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>; <a href="./references#CD013765-bbs2-0009" title="TurcoP , De SimoneA , La RoccaV , IulianoA , CapuanoV , AstaritaC , et al. Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation. Pacing and Clinical Electrophysiology2007;30:S112-5. ">Turco 2007</a>). Overall in combined analysis (Class I and/or III) of data from eight trials, low‐certainty evidence suggests that Class I and/or III antiarrhythmics may reduce the risk of recurrence of ATa during the first three months following ablation for AF (risk ratio (RR) 0.74, 95% confidence interval (CI) 0.59 to 0.94, 8 trials, 3046 participants, low‐certainty evidence) (<a href="./references#CD013765-fig-0004" title="">Analysis 1.1</a>) (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>; <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>; <a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. ">Lodziński 2014</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>; <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>; <a href="./references#CD013765-bbs2-0009" title="TurcoP , De SimoneA , La RoccaV , IulianoA , CapuanoV , AstaritaC , et al. Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation. Pacing and Clinical Electrophysiology2007;30:S112-5. ">Turco 2007</a>). There was evidence of significant heterogeneity (I<sup>2</sup> = 65%, P = 0.006, Tau<sup>2</sup> = 0.06) that was not explained by subgroup analysis by antiarrhythmic class. </p> <p>Aggregated data from five trials provided evidence that Class I and/or III antiarrhythmics likely reduce the risk of recurrence of ATa at &gt; 3 to 6 months after ablation (RR 0.85, 95% CI 0.78 to 0.93, 5 trials, 2591 participants, moderate‐certainty evidence) (<a href="./references#CD013765-fig-0005" title="">Analysis 1.2</a>) (<a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>; <a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. ">Mohanty 2015</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>). Heterogeneity was non‐significant (I<sup>2</sup> = 0%, P &gt; 0.1, Tau<sup>2</sup> = 0), with the directionality of all included trials being in favour of antiarrhythmics. This included the individual analysis of two trials examining either Class I or III antiarrhythmics (excluding trials that examined Class I or III individually), which included the large trial by <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>, and demonstrated that Class I or III antiarrhythmics probably reduce risk of recurrence (RR 0.86, 95% CI 0.78 to 0.94, 2148 participants, 2 trials, moderate‐certainty evidence) (<a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>). </p> <p>However, evidence based on aggregated data from four trials suggests that this effect is uncertain beyond six months (RR 1.14, 95% CI 0.84 to 1.55, 4 trials, 2244 participants, very low‐certainty evidence) (<a href="./references#CD013765-fig-0006" title="">Analysis 1.3</a>) (<a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>; <a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. ">Mohanty 2015</a>; <a href="./references#CD013765-bbs2-0009" title="TurcoP , De SimoneA , La RoccaV , IulianoA , CapuanoV , AstaritaC , et al. Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation. Pacing and Clinical Electrophysiology2007;30:S112-5. ">Turco 2007</a>). There was significant heterogeneity (I<sup>2</sup> = 68%, P = 0.03, Tau<sup>2</sup> = 0.06), predominantly because a single study in the Class III antiarrhythmics group suggested an effect estimate in favour of control (RR 1.95, 95% CI 1.29 to 2.94, 1 trial, 112 participants, moderate‐certainty evidence) (<a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. ">Mohanty 2015</a>). </p> <section id="CD013765-sec-0057"> <h6 class="title">Sensitivity analysis</h6> <p>In our protocol, we stated that we would perform sensitivity analysis by removing trials at 'high' or 'unclear' risk of bias for the following risk of bias domains: random sequence generation, allocation concealment, or incomplete outcome data. This resulted in all trials being removed for our primary outcome for this comparison at &gt; 3 to 6 months and &gt; 6 months time points. However, for the 0 to 3 month time point, <a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a> remained in the analysis and alone showed that antiarrhythmics reduce recurrence of ATa (RR 0.38, 95% CI 0.20 to 0.71, 1 trial, 90 participants, high‐certainty evidence). Removal of trials at high risk of bias for domains other than blinding widened the effect estimates of the primary outcome such that it is uncertain whether antiarrhythmics reduce recurrence of ATa at 0 to 3 months and &gt; 3 to 6 months (0 to 3 months: RR 0.67, 95% CI 0.44 to 1.02, I<sup>2</sup> = 73%, P = 0.002, Tau<sup>2</sup> = 0.18, 6 trials, 792 participants, very low‐certainty evidence; <a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>; <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. ">Lodziński 2014</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>; <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>; <a href="./references#CD013765-bbs2-0009" title="TurcoP , De SimoneA , La RoccaV , IulianoA , CapuanoV , AstaritaC , et al. Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation. Pacing and Clinical Electrophysiology2007;30:S112-5. ">Turco 2007</a>; &gt; 3 to 6 months: RR 0.79, 95% CI 0.55 to 1.15, I<sup>2</sup> = 0%, P &gt; 0.1, Tau<sup>2</sup> = 0, 3 trials, 347 participants, low‐certainty evidence; <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. ">Mohanty 2015</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>). <a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. ">Lodziński 2014</a> was the only trial from which we did not use 100% of the participants in our analysis. Removal in sensitivity analysis did not markedly affect the effect estimate for ATa recurrence at 0 to 3 months (RR 0.69, 95% CI 0.54 to 0.88, I<sup>2</sup> = 64%, P = 0.01, Tau<sup>2</sup> = 0.06, 7 trials, 2936 participants, low‐certainty evidence) (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>; <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>; <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>; <a href="./references#CD013765-bbs2-0009" title="TurcoP , De SimoneA , La RoccaV , IulianoA , CapuanoV , AstaritaC , et al. Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation. Pacing and Clinical Electrophysiology2007;30:S112-5. ">Turco 2007</a>). Removal of <a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>, as the only trial investigating use of antiarrhythmics following surgical ablation, did not change the effect estimate for recurrence of ATa at 0 to 3 months from being in favour of antiarrhythmics (RR 0.80, 95% CI 0.65 to 0.99, 7 trials, 2956 participants, moderate‐certainty evidence) and heterogeneous (I<sup>2</sup> = 57%, P = 0.03, Tau<sup>2</sup> = 0.04). Addition of <a href="./references#CD013765-bbs2-0042" title="StabileG , De Simone, TurcoP , La RoccaV , NocerinoP , AstaritaC , et al. Response to flecainide infusion predicts long-term success of hybrid pharmacologic and ablation therapy in patients with atrial fibrillation. Journal of the American College of Cardiology2001;37(6):1639-44. ">Stabile 2001</a>, a narrowly excluded study, did not markedly change our estimate at &gt; 6 months, although this estimate is of unclear significance due to the very low certainty of the evidence (RR 0.96, 95% CI 0.66 to 1.40, I<sup>2</sup> = 81%, P = 0.04, Tau<sup>2</sup> = 0.14, 5 trials, 2292 participants, very low‐certainty evidence) (<a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>; <a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. ">Lodziński 2014</a>; <a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. ">Mohanty 2015</a>; <a href="./references#CD013765-bbs2-0042" title="StabileG , De Simone, TurcoP , La RoccaV , NocerinoP , AstaritaC , et al. Response to flecainide infusion predicts long-term success of hybrid pharmacologic and ablation therapy in patients with atrial fibrillation. Journal of the American College of Cardiology2001;37(6):1639-44. ">Stabile 2001</a>; <a href="./references#CD013765-bbs2-0009" title="TurcoP , De SimoneA , La RoccaV , IulianoA , CapuanoV , AstaritaC , et al. Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation. Pacing and Clinical Electrophysiology2007;30:S112-5. ">Turco 2007</a>). Removal of <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>, as the only trial including mainly permanent AF, did not alter our conclusions (0 to 3 months: RR 0.75, 95% CI 0.58 to 0.99, I<sup>2</sup> = 66%, P = 0.007, Tau<sup>2</sup> = 0.07, 7 trials, 2834 participants, low‐certainty evidence; &gt; 3 to 6 months: RR 0.85, 0.78 to 0.94, I<sup>2</sup> = 0%, P &gt; 0.1, Tau<sup>2</sup> = 0, 4 trials, 1198 participants, moderate‐certainty evidence) (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>; <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>; <a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. ">Lodziński 2014</a>; <a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. ">Mohanty 2015</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>; <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>; <a href="./references#CD013765-bbs2-0009" title="TurcoP , De SimoneA , La RoccaV , IulianoA , CapuanoV , AstaritaC , et al. Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation. Pacing and Clinical Electrophysiology2007;30:S112-5. ">Turco 2007</a>). Analysis using odds ratios (OR) resulted in more pronounced effect estimates of Class I and/or III antiarrhythmic drugs at 0 to 3 months (OR 0.59, 95% CI 0.41 to 0.86, I<sup>2</sup> = 64%, P = 0.006, Tau<sup>2</sup> = 0.15, 8 trials, 3046 participants, low‐certainty evidence) (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>; <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>; <a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. ">Lodziński 2014</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>; <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>; <a href="./references#CD013765-bbs2-0009" title="TurcoP , De SimoneA , La RoccaV , IulianoA , CapuanoV , AstaritaC , et al. Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation. Pacing and Clinical Electrophysiology2007;30:S112-5. ">Turco 2007</a>); and at &gt; 3 to 6 months (OR 0.75, 95% CI 0.64 to 0.87, I<sup>2</sup> = 0%, P &gt; 0.1, Tau<sup>2</sup> = 0, 5 trials, 2591 participants, moderate‐certainty evidence) (<a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>; <a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. ">Mohanty 2015</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>). </p> <p>The only report of follow‐up data from participants who had undergone a repeat ablation and were then compared according to antiarrhythmics versus control was from a duplicate abstract from <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a> (<a href="./references#CD013765-bbs2-0106" title="TarasovAV , ReynbakhO , DavtyanKV , MartsevichSY . 1670 Antiarrhythmic drugs in blanking period after catheter ablation of atrial fibrillation do not change effectiveness of the procedure but add clinical benefit. Europace2017;19(Suppl 3):iii356.">Tarasov 2017a</a>). They reported equal "effectiveness" of antiarrhythmic drugs versus no antiarrhythmic drugs (88.6% versus 88.3%, respectively). However, it is likely that the intervention group of antiarrhythmic drugs also included the non‐Class I and/or III antiarrhythmic verapamil, in addition to propafenone and sotalol. Consequently, we did not include these data in meta‐analysis. </p> </section> </section> <section id="CD013765-sec-0058"> <h5 class="title">Adverse events: thromboembolic events</h5> <p>Three trials (2340 participants, 6 cases) provided low‐ to very low‐certainty evidence suggesting no difference in thromboembolic events between antiarrhythmics and control at 0 to 3 months (0 events, 1 trial, 90 participants, low‐certainty evidence) (<a href="./references#CD013765-fig-0007" title="">Analysis 1.4</a>) (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>); &gt; 3 to 6 months (Peto OR 0.96, 95% CI 0.06 to 15.50, 1 trial, 212 participants, very low‐certainty evidence) (<a href="./references#CD013765-fig-0008" title="">Analysis 1.5</a>) (<a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>); and &gt; 6 months (Peto OR 2.74, 95% CI 0.39 to 19.47, 1 trial, 2038 participants, very low‐certainty evidence) (<a href="./references#CD013765-fig-0009" title="">Analysis 1.6</a>) (<a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>). Combining these time points produced consistent results (Peto OR 1.93, 95% CI 0.39 to 9.60, I<sup>2</sup> = 0%, P &gt; 0.1, 3 trials, 2340 participants, very low‐certainty evidence) (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>; <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>). </p> <section id="CD013765-sec-0059"> <h6 class="title">Sensitivity analysis</h6> <p>Sensitivity analysis at &gt; 3 to 6 months including only studies at low risk of bias or those without missing data was not possible. </p> </section> </section> <section id="CD013765-sec-0060"> <h5 class="title">Adverse events: myocardial infarction</h5> <p>Only one trial (2038 participants, 2 cases) (<a href="./references#CD013765-fig-0010" title="">Analysis 1.7</a>) provided data on rates of myocardial infarction in both Class I and/or III antiarrhythmic and control groups, and suggested no distinguishable difference (Peto OR 1.01, 95% CI 0.06 to 16.1, 1 trial, 2038 participants, very low‐certainty evidence) (<a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>). </p> <section id="CD013765-sec-0061"> <h6 class="title">Sensitivity analysis</h6> <p>Sensitivity analysis at &gt; 3 to 6 months including only studies at low risk of bias or those without missing data was not possible. </p> </section> </section> <section id="CD013765-sec-0062"> <h5 class="title">Adverse events: new diagnosis of heart failure</h5> <p>No data were available for this outcome.</p> </section> <section id="CD013765-sec-0063"> <h5 class="title">Adverse events: requirement for one or more hospitalisations for atrial tachyarrhythmias</h5> <p>In meta‐analysis of three trials (448 participants) at 0 to 3 months after ablation, there was moderate‐certainty evidence of a large reduction in rates of hospitalisation with Class I and/or III antiarrhythmics versus control (RR 0.43, 95% CI 0.28 to 0.64, 3 trials, 448 participants, moderate‐certainty evidence) (<a href="./references#CD013765-fig-0011" title="">Analysis 1.8</a>) (<a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>). There was no evidence of heterogeneity (I<sup>2</sup> = 0%, P &gt; 0.1, Tau<sup>2</sup> = 0). This estimate equates to a number needed to treat for an additional beneficial outcome (NNTB) of 7 (95% CI 5 to 10). It was not possible to stratify individual studies by time of follow‐up beyond three months (mean 2.5 ±0.87 months, range 1.5 to 3 months) (<a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>). Moreover, <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a> reported mean ±SD "hospitalisations for arrhythmia" at three‐month follow‐up that were consistent with our findings (propafenone: 0.45 and sotalol: 0.59 versus verapamil: 0.68 and no antiarrhythmics: 0.89). </p> <section id="CD013765-sec-0064"> <h6 class="title">Sensitivity analysis</h6> <p>In sensitivity analysis, as stated a priori, we removed trials that were 'high' or 'unclear' risk of bias for the following risk of bias domains: random sequence generation, allocation concealment, and incomplete outcome data. As for our primary outcome of recurrence of ATa, this resulted in all trials being removed for this outcome. Removal of trials at high risk of bias for domains other than blinding widened the effect estimate for requirement for one or more hospitalisations for ATa at 0 to 3 months (RR 0.57, 95% CI 0.21 to 1.51, I<sup>2</sup> = 0%, P &gt; 0.1, Tau<sup>2</sup> = 0, 2 trials, 236 participants, moderate‐certainty evidence) (<a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>). <a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a> did not specify whether their "readmission" rate was for reasons related to ATa. Similarly, <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a> did not report hospitalisation secondary to ATa, but did provide data on cardioversion at &lt; 90 days and ≥ 90 days, which produced opposing results. Furthermore, sensitivity analysis examining all‐cause hospitalisation (follow‐up range 3 months to median 387 days) showed that antiarrhythmics likely lead to fewer hospitalisations (RR 0.47, 95% CI 0.32 to 0.68, I<sup>2</sup> = 0%, P &gt; 0.1, Tau<sup>2</sup> = 0, 5 trials, 2576 participants, moderate‐certainty evidence) (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>; <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>). Furthermore, meta‐analysis of all‐cause hospitalisation or cardioversion at up to six months remained in favour of antiarrhythmics reducing hospitalisations with minimal, insignificant heterogeneity (RR 0.59, 95% CI 0.39 to 0.90, I<sup>2</sup> = 47%, P &gt; 0.1, Tau<sup>2</sup> = 0.09, 5 trials, 2576 participants, low‐certainty evidence) (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>; <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>), although <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a> provided data on requirement of cardioversion at &gt; 3 months suggesting that this effect does not persist long term (RR 2.17, 95% CI 1.13 to 4.16, 1 trial, 2038 participants, moderate‐certainty evidence). This is consistent with data from <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a> which provided a rate ratio of hospitalisation for ATa for the entire duration of the study that was non‐significant in comparison to their data from the blanking period used in the above analysis (RR 0.59, 95% CI 0.32 to 1.06, P &gt; 0.05, 1 trial, 212 participants). Sensitivity analysis at &gt; 3 to 6 months including only studies at low risk of bias or those without missing data was not possible. </p> </section> </section> <section id="CD013765-sec-0065"> <h5 class="title">All‐cause mortality</h5> <p>Based on low‐ to moderate‐certainty evidence from three trials (2340 participants, 8 cases), there did not appear to be any effect of Class I and/or III antiarrhythmics use after ablation on all‐cause mortality at 0 to 3 months (Peto OR 0.13, 95% CI 0.00 to 6.57, 1 trial, 212 participants, moderate‐certainty evidence) (<a href="./references#CD013765-fig-0012" title="">Analysis 1.9</a>) (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>); &gt; 3 to 6 months (Peto OR 1.00, 95% CI 0.06 to 16.24, 1 trial, 90 participants, low‐certainty evidence) (<a href="./references#CD013765-fig-0013" title="">Analysis 1.10</a>) (<a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>); and &gt; 6 months (Peto OR 1.50, 95% CI 0.26 to 8.68, 1 trial, 2038 participants, low‐certainty evidence) (<a href="./references#CD013765-fig-0014" title="">Analysis 1.11</a>) (<a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>). Combining all three time points also supported this assertion (Peto OR 1.00, 95% CI 0.25 to 4.01, I<sup>2</sup> = 0%, P &gt; 0.1, 3 trials, 2340 participants, low‐certainty evidence) (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>; <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>). </p> <section id="CD013765-sec-0066"> <h6 class="title">Sensitivity analysis</h6> <p>Sensitivity analysis at &gt; 3 to 6 months including only studies at low risk of bias or those without missing data was not possible. </p> </section> </section> <section id="CD013765-sec-0067"> <h5 class="title">Requirement for one or more repeat ablation</h5> <p>Based on data from four trials, it was unclear if Class I and/or III antiarrhythmics have any effect on repeat ablation at 0 to 3 months after ablation versus control (RR 1.10, 95% CI 0.61 to 2.00, I<sup>2</sup> = 53%, P &gt; 0.1, Tau<sup>2</sup> = 0.13, 3 trials, 567 participants, very low‐certainty evidence) (<a href="./references#CD013765-fig-0015" title="">Analysis 1.12</a>) (<a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. ">Mohanty 2015</a>; <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>). At &gt; 3 to 6 months after ablation, the evidence suggests that Class I and/or III antiarrhythmics may not affect the requirement for repeat ablation (RR 0.95, 95% CI 0.79 to 1.13, 1 trial, 1365 participants, low‐certainty evidence) (<a href="./references#CD013765-fig-0016" title="">Analysis 1.13</a>) (<a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>). Combining these time points also produced unclear results (RR 1.02, 95% CI 0.80 to 1.30, 4 trials, 1932 participants, very low‐certainty evidence), with evidence of heterogeneity (I<sup>2</sup> = 27%, P &gt; 0.1, Tau<sup>2</sup> = 0.02) (<a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>; <a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. ">Mohanty 2015</a>; <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>). </p> <section id="CD013765-sec-0068"> <h6 class="title">Sensitivity analysis</h6> <p>Sensitivity analysis at &gt; 3 to 6 months including only studies at low risk of bias or those without missing data was not possible. </p> </section> </section> </section> <section id="CD013765-sec-0069"> <h4 class="title">Class I antiarrhythmics versus control</h4> <p>See <a href="./full#CD013765-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD013765-sec-0070"> <h5 class="title">Recurrence of atrial tachyarrhythmias</h5> <p>Analysis based on data from one to two trials showed that Class I antiarrhythmics do not appear to reduce recurrence of ATa at 0 to 3, &gt; 3 to 6, and &gt; 6 months (0 to 3 months: RR 0.88, 95% CI 0.64 to 1.20, I<sup>2</sup> = 0%, P &gt; 0.1, Tau<sup>2</sup> = 0, 2 trials, 309 participants, low‐certainty evidence; &gt; 3 to 6 months: RR 0.54, 95% CI 0.25 to 1.19, 1 trial, 125 participants, low‐certainty evidence; &gt; 6 months: RR 0.87, 95% CI 0.57 to 1.32, 1 trial, 125 participants, low‐certainty evidence) (<a href="./references#CD013765-fig-0017" title="">Analysis 2.1</a>; <a href="./references#CD013765-fig-0018" title="">Analysis 2.2</a>; <a href="./references#CD013765-fig-0019" title="">Analysis 2.3</a>) (<a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>). </p> <section id="CD013765-sec-0071"> <h6 class="title">Sensitivity analysis</h6> <p>Sensitivity analysis including only studies at low risk of bias or those without missing data was not possible. </p> </section> </section> <section id="CD013765-sec-0072"> <h5 class="title">Adverse events: thromboembolic events</h5> <p>No data were available for this outcome.</p> </section> <section id="CD013765-sec-0073"> <h5 class="title">Adverse events: myocardial infarction</h5> <p>No data were available for this outcome.</p> </section> <section id="CD013765-sec-0074"> <h5 class="title">Adverse events: new diagnosis of heart failure</h5> <p>No data were available for this outcome.</p> </section> <section id="CD013765-sec-0075"> <h5 class="title">Adverse events: requirement for one or more hospitalisations for atrial tachyarrhythmias</h5> <p>Only one trial reported Class I data on postablation hospitalisation for ATa, showing that Class I antiarrhythmics may have little effect on reducing hospitalisation (RR 0.34, 95% CI 0.01 to 8.28, 1 trial, 126 participants, low‐certainty evidence) (<a href="./references#CD013765-fig-0020" title="">Analysis 2.4</a>) (<a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>). </p> <section id="CD013765-sec-0076"> <h6 class="title">Sensitivity analysis</h6> <p>Sensitivity analysis including only studies at low risk of bias or those without missing data was not possible. </p> </section> </section> <section id="CD013765-sec-0077"> <h5 class="title">All‐cause mortality</h5> <p>No data were available for this outcome.</p> </section> <section id="CD013765-sec-0078"> <h5 class="title">Requirement for one or more repeat ablation</h5> <p>Evidence from only one trial showed that Class I antiarrhythmics may have little effect in reducing repeat ablations (RR 0.88, 95% CI 0.51 to 1.53, 1 trial, 183 participants, low‐certainty evidence) (<a href="./references#CD013765-fig-0021" title="">Analysis 2.5</a>) (<a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>). </p> <section id="CD013765-sec-0079"> <h6 class="title">Sensitivity analysis</h6> <p>Sensitivity analysis including only studies at low risk of bias or those without missing data was not possible. </p> </section> </section> </section> <section id="CD013765-sec-0080"> <h4 class="title">Class III antiarrhythmics versus control</h4> <p>See <a href="./full#CD013765-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD013765-sec-0081"> <h5 class="title">Recurrence of atrial tachyarrhythmias</h5> <p>Based on pooled data from four trials, Class III antiarrhythmics alone may have little effect on recurrence of ATa at 0 to 3 months (RR 0.76, 95% CI 0.50 to 1.16, I<sup>2</sup> = 75%, P &lt; 0.01, Tau<sup>2</sup> = 0.13, low‐certainty evidence) (<a href="./references#CD013765-fig-0022" title="">Analysis 3.1</a>) (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>; <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. ">Lodziński 2014</a>; <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>). Class III antiarrhythmics may also have little effect on recurrence at &gt; 3 to 6 months (RR 0.82, 95% CI 0.62 to 1.09, I<sup>2</sup> = 0%, P &gt; 0.1, Tau<sup>2</sup> = 0.00, low‐certainty evidence) (<a href="./references#CD013765-fig-0023" title="">Analysis 3.2</a>) (<a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. ">Mohanty 2015</a>). <a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. ">Mohanty 2015</a> was the only trial to investigate a Class III antiarrhythmic (amiodarone) after six months, reporting a possible higher ATa recurrence (RR 1.95, 95% CI 1.29 to 2.94, 1 trial, 112 participants, low‐certainty evidence) (<a href="./references#CD013765-fig-0024" title="">Analysis 3.3</a>). However, this was not consistent with findings from trials that investigated Class I and III antiarrhythmics (<a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>; <a href="./references#CD013765-bbs2-0009" title="TurcoP , De SimoneA , La RoccaV , IulianoA , CapuanoV , AstaritaC , et al. Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation. Pacing and Clinical Electrophysiology2007;30:S112-5. ">Turco 2007</a>). </p> <section id="CD013765-sec-0082"> <h6 class="title">Sensitivity analysis</h6> <p>Removal of trials that were 'high' or 'unclear' risk of bias for the risk of bias domains random sequence generation, allocation concealment, and incomplete outcome data showed that Class III antiarrhythmics reduce recurrence of ATa at 0 to 3 months (RR 0.38, 95% CI 0.20 to 0.71, 1 trial, 90 participants, high‐certainty evidence) (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>). Sensitivity analysis for missing data was not necessary. We utilised data from a subgroup of <a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. ">Lodziński 2014</a>; following exclusion of these data, the evidence for recurrence of ATa with Class III antiarrhythmics at 0 to 3 months remained unclear (RR 0.66, 95% CI 0.41 to 1.05, I<sup>2</sup> = 70%, P &lt; 0.1, Tau<sup>2</sup> = 0.12, 3 trials, 483 participants, very low‐certainty evidence) (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>; <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>). Despite the removal of <a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a> as the only included trial investigating use of antiarrhythmics following surgical ablation, the estimate for Class III antiarrhythmics at 0 to 3 months remained similar (RR 0.90, 95% CI 0.62 to 1.29, I<sup>2</sup> = 66%, P &lt; 0.1, Tau<sup>2</sup> = 0.07, 3 trials, 509 participants, very low‐certainty evidence). The addition of <a href="./references#CD013765-bbs2-0042" title="StabileG , De Simone, TurcoP , La RoccaV , NocerinoP , AstaritaC , et al. Response to flecainide infusion predicts long-term success of hybrid pharmacologic and ablation therapy in patients with atrial fibrillation. Journal of the American College of Cardiology2001;37(6):1639-44. ">Stabile 2001</a>, a narrowly excluded study, suggested that Class III antiarrhythmics may have little effect on recurrence at &gt; 6 months (RR 0.64, 95% CI 0.34 to 1.21, I<sup>2</sup> = 75%, P &lt; 0.1, Tau<sup>2</sup> = 0.16, 2 trials, 160 participants, low‐certainty evidence) (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>; <a href="./references#CD013765-bbs2-0042" title="StabileG , De Simone, TurcoP , La RoccaV , NocerinoP , AstaritaC , et al. Response to flecainide infusion predicts long-term success of hybrid pharmacologic and ablation therapy in patients with atrial fibrillation. Journal of the American College of Cardiology2001;37(6):1639-44. ">Stabile 2001</a>). <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a> was the only trial to include mainly permanent AF; removal of this study did not change our conclusions for Class III antiarrhythmics at 0 to 3 months and &gt; 3 to 6 months (RR 0.80, 95% CI 0.45 to 1.43, 3 trials, 387 participants, low‐certainty evidence; RR 0.88, 95% CI 0.47 to 1.62, 1 trial, 112 participants, low‐certainty evidence, respectively) (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>; <a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. ">Lodziński 2014</a>; <a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. ">Mohanty 2015</a>; <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>). </p> </section> </section> <section id="CD013765-sec-0083"> <h5 class="title">Adverse events: thromboembolic events</h5> <p>Based on very low‐certainty evidence, it is unclear whether Class III antiarrhythmics have any effect on thromboembolic events following ablation at 0 to 3 months (not estimatable due to no events, 1 trial, 90 participants) (<a href="./references#CD013765-fig-0025" title="">Analysis 3.4</a>) (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>); or &gt; 3 to 6 months (Peto OR 0.96, 95% CI 0.06 to 15.5, 1 trial, 212 participants, very low‐certainty evidence) (<a href="./references#CD013765-fig-0026" title="">Analysis 3.5</a>) (<a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>). </p> <section id="CD013765-sec-0084"> <h6 class="title">Sensitivity analysis</h6> <p>Sensitivity analysis including only studies at low risk of bias at 0 to 3 months was consistent with the estimate above, and was not possible at &gt; 3 to 6 months. Sensitivity analysis on the basis of missing data was not necessary. </p> </section> </section> <section id="CD013765-sec-0085"> <h5 class="title">Adverse events: myocardial infarction</h5> <p>No data were available for this outcome.</p> </section> <section id="CD013765-sec-0086"> <h5 class="title">Adverse events: new diagnosis of heart failure</h5> <p>No data were available for this outcome.</p> </section> <section id="CD013765-sec-0087"> <h5 class="title">Adverse events: requirement for one or more hospitalisations for atrial tachyarrhythmias</h5> <p>One trial reported that Class III antiarrhythmics likely reduce hospitalisations for ATa substantially at 0 to 3 months (RR 0.40, 95% CI 0.26 to 0.63, 1 trial, 212 participants, moderate‐certainty evidence) (<a href="./references#CD013765-fig-0027" title="">Analysis 3.6</a>) (<a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>). </p> <section id="CD013765-sec-0088"> <h6 class="title">Sensitivity analysis</h6> <p>Sensitivity analysis including only studies at low risk of bias or those without missing data was not possible. </p> </section> </section> <section id="CD013765-sec-0089"> <h5 class="title">All‐cause mortality</h5> <p>At 0 to 3 months, evidence from <a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a> suggests that Class III antiarrhythmics do not affect all‐cause mortality (Peto OR 1.00, 95% CI 0.06 to 16.24, 1 trial, 90 participants, low‐certainty evidence) (<a href="./references#CD013765-fig-0028" title="">Analysis 3.7</a>) (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>). At &gt; 3 to 6 months, it is unclear whether Class III antiarrhythmics affect all‐cause mortality (Peto OR 0.13, 95% CI 0.00 to 6.57, 1 trial, 212 participants, very low‐certainty evidence) (<a href="./references#CD013765-fig-0029" title="">Analysis 3.8</a>) (<a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>). </p> <section id="CD013765-sec-0090"> <h6 class="title">Sensitivity analysis</h6> <p>Sensitivity analysis including only studies at low risk of bias at 0 to 3 months was consistent with the estimate above, and was not possible at &gt; 3 to 6 months. Sensitivity analysis on the basis of missing data was not necessary. </p> </section> </section> <section id="CD013765-sec-0091"> <h5 class="title">Requirement for one or more repeat ablation</h5> <p>Based on the analysis of three trials, it is unclear whether Class III antiarrhythmics affect requirement for repeat ablation 0 to 3 months after ablation (RR 1.18, 95% CI 0.66 to 2.11, I<sup>2</sup> = 46%, P &gt; 0.05, Tau<sup>2</sup> = 0.11, 3 trials, 505 participants, very low‐certainty evidence) (<a href="./references#CD013765-fig-0030" title="">Analysis 3.9</a>) (<a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. ">Mohanty 2015</a>; <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>). <a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. ">Mohanty 2015</a> did not specify the timing of re‐ablation. </p> <section id="CD013765-sec-0092"> <h6 class="title">Sensitivity analysis</h6> <p>Sensitivity analysis at &gt; 3 to 6 months including only studies at low risk of bias or those without missing data was not possible. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013765-sec-0093" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013765-sec-0093"></div> <section id="CD013765-sec-0094"> <h3 class="title" id="CD013765-sec-0094">Summary of main results</h3> <p>This review examined the effect of oral Class I and/or III antiarrhythmics versus no antiarrhythmics in the maintenance of sinus rhythm following catheter ablation for AF. We identified and included 9 parallel‐group RCTs involving 3269 participants. For our first primary outcome, recurrence of ATa, the evidence showed a possible benefit of Class I and/or III antiarrhythmics (overall group) in reducing rates of ATa recurrence during the blanking phase (0 to 3 months) (RR 0.74, 95% CI 0.59 to 0.94, 8 trials, 3046 participants, low‐certainty evidence), and a likely benefit in reducing rates at &gt; 3 to 6 months (RR 0.85, 95% CI 0.78 to 0.93, 5 trials, 2591 participants, moderate‐certainty evidence). This benefit of antiarrhythmics did not appear to last beyond six months (RR 1.14, 95% CI 0.84 to 1.55, 4 trials, 2244 participants, very low‐certainty evidence). In addition to a reduction of ATa up to six months after the blanking period, hospitalisations for ATa were reduced with the use of antiarrhythmics up to three months after ablation (RR 0.43, 95% CI 0.28 to 0.64, 3 trials, 448 participants, moderate‐certainty evidence). Furthermore, sensitivity analysis supported these results for all‐cause hospitalisations (0 to &gt; 6 month follow‐up: RR 0.47, 95% CI 0.32 to 0.68, I<sup>2</sup> = 0%, P &gt; 0.1, Tau<sup>2</sup> = 0, 5 trials, 2576 participants, moderate‐certainty evidence) and hospitalisations/cardioversions (0 to &gt; 6 month follow‐up: RR 0.59, 95% CI 0.39 to 0.90, I<sup>2</sup> = 47%, P &gt; 0.1, Tau<sup>2</sup> = 0.09, 5 trials, 2576 participants, low‐certainty evidence). We found no evidence suggesting a beneficial or detrimental effect of antiarrhythmics or lack of antiarrhythmics for the other adverse events or other outcomes of interest for which sufficient data were available: all‐cause mortality, requirement for one or more repeat ablation, thromboembolic events, and myocardial infarction. Regarding the three outcomes for which there were very low event rates (all‐cause mortality, thromboembolic events, and myocardial infarction), when considering number needed to treat for one additional harmful outcome (NNTH), none of the outcomes NNTH exceeded 100, thus assuming patients are willing to accept an absolute risk of ≤ 1%, we can conclude the risk of these adverse events to be equal between antiarrhythmics and control. It is important to bear in mind that the studies included in this review only prescribed antiarrhythmics up to three months. </p> </section> <section id="CD013765-sec-0095"> <h3 class="title" id="CD013765-sec-0095">Overall completeness and applicability of evidence</h3> <p>This review constitutes the most up‐to‐date, complete appraisal of evidence regarding the benefits of short‐term Class I and/or III antiarrhythmic therapy (up to three months) in maintaining sinus rhythm following ablation for AF. The search was comprehensive and was performed in the CENTRAL, MEDLINE, Embase, Web of Science Core Collection databases and in clinical trials registries. We identified one trial registry protocol that is likely eligible and appears to be in progress (<a href="./references#CD013765-bbs2-0029" title="NCT02913014. Comparison of recurrence of atrial fibrillation post cryoballon ablation during the 90-day blanking period - with and without anti-arrhythmic drug therapy. clinicaltrials.gov/ct2/show/NCT02913014 (first received 23 September 2016). ">NCT02913014</a>). </p> <p>All included trials reported recurrence of ATa, at various follow‐up periods after ablation; for five trials this was their primary outcome, or at least part of it (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>; <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>). Our seven outcomes of interest covered the vast majority of data reported in the included studies, except for cardioversion; requirement for electrical cardioversion was reported in seven included trials (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>; <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>; <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>; <a href="./references#CD013765-bbs2-0009" title="TurcoP , De SimoneA , La RoccaV , IulianoA , CapuanoV , AstaritaC , et al. Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation. Pacing and Clinical Electrophysiology2007;30:S112-5. ">Turco 2007</a>). That being said, for many of our included trials these data will overlap with the data reported on hospitalisations for ATa, and in one case was confirmed to do so (<a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>). </p> <p>It is worth noting that one trial reported data on recurrence of ATa to &gt; 24 hours, thus it is possible that this study missed shorter episodes of recurrence. However, as <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a> made up 2% and 2.5% of the weighting for the 0 to 3 month and &gt; 3 to 6 month primary outcome analyses, it is unlikely to have had a substantial effect on our conclusions. </p> <p>Of note, none of the included studies continued to prescribe Class I and/or III antiarrhythmics beyond three months following ablation. Most included participants had paroxysmal AF (72.8%), whilst the remainder mainly had persistent AF (27.4%). The characteristics of included studies would be applicable to clinical practice; the use of antiarrhythmics in all cases was within the clinically appropriate dosage; and outcomes were all relevant to clinical practice. </p> <p>Due to an insufficient number of pooled studies, it was not feasible to perform subgroup analysis by individual antiarrhythmic drug or by first versus successive ablations. This will be reviewed in future iterations. </p> </section> <section id="CD013765-sec-0096"> <h3 class="title" id="CD013765-sec-0096">Quality of the evidence</h3> <p>We assessed the certainty of the evidence according to the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013765-bbs2-0076" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011a</a>), using the GRADE approach (<a href="./references#CD013765-bbs2-0101" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.">Schünemann 2013</a>). An inclusion criterion of our review was that all studies had to be RCTs. Based on the risk of bias domains random sequence generation, allocation concealment, incomplete outcome data, selective reporting, and other bias, we considered one trial to be at low risk of bias (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>), six trials as at unclear risk of bias (<a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. ">Lodziński 2014</a>; <a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. ">Mohanty 2015</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>; <a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. ">Tarasov 2017</a>; <a href="./references#CD013765-bbs2-0009" title="TurcoP , De SimoneA , La RoccaV , IulianoA , CapuanoV , AstaritaC , et al. Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation. Pacing and Clinical Electrophysiology2007;30:S112-5. ">Turco 2007</a>), and two trials as at high risk of bias (<a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>). </p> <p>In assessing the limitations of studies, only <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a> reported limitations sufficient to merit a judgement of high risk of bias for random sequence generation, due to a randomisation programming error. <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a> excluded participants that were lost to follow‐up, and so was considered to be at high risk of bias for incomplete outcome data. <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a> reported an extensive ablation strategy that is likely to be more intensive than routine practice; however, the participants from this trial were the minority of all participants included in the outcomes to which the trial provided data, thus not meriting downgrading of the certainty of evidence for these outcomes. Four trials highlighted the potential risk of missing recurrence events due to the lack of loop recorders (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>; <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. ">Lodziński 2014</a>); however, this did not merit a judgement of low risk of bias because the data represented a reliable measurement of incidence that is equal across control and intervention arms. <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a> described the exclusion of persistent AF as a limitation; this did not merit a judgement of low risk of bias, as overall the proportions of paroxysmal and persistent AF in the studies included in meta‐analysis were relevant to clinical practice. <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a> and <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a> considered that the doses of antiarrhythmics they used may have been lower or different than those routinely used in Western countries, but they were applicable to the countries where the studies were conducted, thereby improving the generalisability of this review. </p> <p>We downgraded the certainty of the evidence for imprecision for the following outcomes: recurrence of ATa at 0 to 3, &gt; 3 to 6, and &gt; 6 months with Class I antiarrhythmics, and at &gt; 6 months with Class III antiarrhythmics; 'requirement for one or more hospitalisations for ATa' at 0 to 3 months with Class III antiarrhythmics and 0 to 3 months with Class I antiarrhythmics; and requirement for one or more repeat ablation at 0 to 3 months with Class I antiarrhythmics, as the optimal information size was higher than the total participant numbers in the analysis. Further details of imprecision leading to downgrading of the certainty of the evidence for our main time point of interest are provided in the footnotes of the summary of findings tables. </p> <p>We did not consider indirectness to be an issue given our stringent inclusion criteria. We were not able to investigate for publication bias, as we did not include &gt; 10 studies (<a href="./references#CD013765-bbs2-0067" title="EggerM , SmithGD , SchneiderM , ChristophM . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315:629.">Egger 1997</a>). </p> <p>Of note, it is possible that the reassuringly low mortality data may well reflect the fact that ablation is performed in a less comorbid population selected for the procedure, thus introducing a risk of selection bias. Nonetheless, this is an internally consistent feature of this review, and so conclusions are therefore limited to the detailed demographic (see <a href="#CD013765-tbl-0004">Table 1</a>). </p> </section> <section id="CD013765-sec-0097"> <h3 class="title" id="CD013765-sec-0097">Potential biases in the review process</h3> <p>This systematic review was undertaken in accordance with the standards detailed in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013765-bbs2-0076" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011a</a>). We employed a comprehensive search of the most relevant databases. We performed backward citation searches on the included studies. The flow of studies through the review has been transparently outlined in full (<a href="#CD013765-fig-0001">Figure 1</a>). We applied no language or date restrictions. At least two review authors (CP, JJHB, MA, MWa, MWh, or RB) assessed studies for inclusion; two review authors (JJHB and CP, MWa, MWh, or RB) independently collected data and information on risk of bias; data collection was checked by MA, CP, MWa, and JJHB; and analyses were performed by JJHB and checked by another review author (JJHB and CP, MWa, MWh, or RB). Any disagreements were resolved through discussion and consensus. Reasons for exclusion of the excluded studies have been provided. Where information was not available, we contacted the study authors, but have received no response. </p> <p>Our conclusion for the outcome 'requirement for one or more hospitalisations for ATa' is based on a minority of included studies (<a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>), and thus may not be as generalisable as, for example, our first primary outcome, recurrence of ATa. As part of our sensitivity analysis of whether antiarrhythmics do indeed reduce hospitalisation, we broadened the inclusion criteria to also include 'all‐cause hospitalisation' and 'cardioversion' (as cardioversion is most likely to take place during a hospital admission), and found consistent results in favour of antiarrhythmics reducing all of these events by approximately 40% (<a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. ">Ad 2016</a>; <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>; <a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. ">Hayashi 2014</a>; <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>; <a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. ">Roux 2009</a>). Due to a lack of data, it was not possible to divide secondary outcomes by time points. As previously mentioned, we were not able to assess for publication bias. </p> </section> <section id="CD013765-sec-0098"> <h3 class="title" id="CD013765-sec-0098">Agreements and disagreements with other studies or reviews</h3> <p>Our results both agree with and differ from two previous systematic reviews (<a href="./references#CD013765-bbs2-0070" title="GoldenbergGR , BurdD , LodzinskiP , StabileG , UdellJA , NewmanD , et al. Antiarrhythmic therapy as an adjuvant to promote postpulmonary vein isolation success - a meta-analysis. Journal of Interventional Cardiac Electrophysiology: an International Journal of Arrhythmias and Pacing2016;47(2):171-6.">Goldenberg 2016</a>; <a href="./references#CD013765-bbs2-0110" title="XuX , AlidaCT , YuB . Administration of antiarrhythmic drugs to maintain sinus rhythm after catheter ablation for atrial fibrillation: a meta-analysis. Cardiovascular Therapeutics2015;33(4):242-6. [DOI: 10.1111/1755-5922.12133]">Xu 2015</a>). Similar to our findings, <a href="./references#CD013765-bbs2-0110" title="XuX , AlidaCT , YuB . Administration of antiarrhythmic drugs to maintain sinus rhythm after catheter ablation for atrial fibrillation: a meta-analysis. Cardiovascular Therapeutics2015;33(4):242-6. [DOI: 10.1111/1755-5922.12133]">Xu 2015</a> concluded that antiarrhythmic drugs reduce the early reoccurrence of AF after catheter ablation, but not long‐term reoccurrence. However, that review diverges from our meta‐analysis in finding early reoccurrence to be twice as likely without the use of antiarrhythmics (our estimates were 24% less at 0 to 3 months and 15% less at &gt; 3 to 6 months). <a href="./references#CD013765-bbs2-0070" title="GoldenbergGR , BurdD , LodzinskiP , StabileG , UdellJA , NewmanD , et al. Antiarrhythmic therapy as an adjuvant to promote postpulmonary vein isolation success - a meta-analysis. Journal of Interventional Cardiac Electrophysiology: an International Journal of Arrhythmias and Pacing2016;47(2):171-6.">Goldenberg 2016</a> found consistent trends in "overall effect" of antiarrhythmics and in their sensitivity analysis that were not significant. Both <a href="./references#CD013765-bbs2-0070" title="GoldenbergGR , BurdD , LodzinskiP , StabileG , UdellJA , NewmanD , et al. Antiarrhythmic therapy as an adjuvant to promote postpulmonary vein isolation success - a meta-analysis. Journal of Interventional Cardiac Electrophysiology: an International Journal of Arrhythmias and Pacing2016;47(2):171-6.">Goldenberg 2016</a> and <a href="./references#CD013765-bbs2-0110" title="XuX , AlidaCT , YuB . Administration of antiarrhythmic drugs to maintain sinus rhythm after catheter ablation for atrial fibrillation: a meta-analysis. Cardiovascular Therapeutics2015;33(4):242-6. [DOI: 10.1111/1755-5922.12133]">Xu 2015</a> included fewer studies than our review: <a href="./references#CD013765-bbs2-0070" title="GoldenbergGR , BurdD , LodzinskiP , StabileG , UdellJA , NewmanD , et al. Antiarrhythmic therapy as an adjuvant to promote postpulmonary vein isolation success - a meta-analysis. Journal of Interventional Cardiac Electrophysiology: an International Journal of Arrhythmias and Pacing2016;47(2):171-6.">Goldenberg 2016</a> included 8 studies (2952 participants) and <a href="./references#CD013765-bbs2-0110" title="XuX , AlidaCT , YuB . Administration of antiarrhythmic drugs to maintain sinus rhythm after catheter ablation for atrial fibrillation: a meta-analysis. Cardiovascular Therapeutics2015;33(4):242-6. [DOI: 10.1111/1755-5922.12133]">Xu 2015</a> included 6 studies (814 participants), whereas our review included 9 studies (3269 participants). It should also be noted that <a href="./references#CD013765-bbs2-0110" title="XuX , AlidaCT , YuB . Administration of antiarrhythmic drugs to maintain sinus rhythm after catheter ablation for atrial fibrillation: a meta-analysis. Cardiovascular Therapeutics2015;33(4):242-6. [DOI: 10.1111/1755-5922.12133]">Xu 2015</a> only evaluated participants in two groups: 0 to 3 months and 3 months onwards, and <a href="./references#CD013765-bbs2-0070" title="GoldenbergGR , BurdD , LodzinskiP , StabileG , UdellJA , NewmanD , et al. Antiarrhythmic therapy as an adjuvant to promote postpulmonary vein isolation success - a meta-analysis. Journal of Interventional Cardiac Electrophysiology: an International Journal of Arrhythmias and Pacing2016;47(2):171-6.">Goldenberg 2016</a> did not subgroup by follow‐up time. </p> <p>Our review included studies that prescribed Class I and/or III antiarrhythmics up to three months after ablation. In a moderately sized, multicentre RCT performed by <a href="./references#CD013765-bbs2-0066" title="DuytschaeverM , DemolderA , PhlipsT , SarkozyA , El HaddadM , TaghjiP , et al. PulmOnary vein isolation With vs. without continued antiarrhythmic Drug trEatment in subjects with Recurrent Atrial Fibrillation (POWDER AF): results from a multicentre randomized trial. European Heart Journal2018;39(16):1429-37.">Duytschaever 2018</a>, participants who had had catheter ablation undertaken for AF and who had received an extended period of antiarrhythmics (1 year) had markedly lower rates of ATa recurrence at 12‐month follow‐up compared with control, who had received antiarrhythmics for the first 3 months (21.9% versus 2.7%, respectively). Consequently, stopping antiarrhythmics at three months may explain our findings that any benefit of antiarrhythmics appears to wane after six months. Our findings are also similar to <a href="./references#CD013765-bbs2-0051" title="WuG , JiangH , Huang C-X, YangB , HuangH , Wang Y-L, et al. Effects of antiarrhythmic drug use on atrial fibrillation recurrence in atrial fibrillation patients post circumferential pulmonary vein ablation. Zhonghua Xin Xue Guan Bing Za Zhi [Chinese Journal of Cardiology]2008;36(7):623-6. ">Wu 2008</a>, a narrowly excluded study that found significant differences in AF recurrence following antiarrhythmics for 3 months at 3‐month follow‐up, but not at 12‐month follow‐up. The same is true when comparing our results with <a href="./references#CD013765-bbs2-0073" title="GuJ , LiuX , TanH , ZhouL , GuJ , JiangW , et al. Extensive antiarrhythmic drugs after catheter ablation of persistent atrial fibrillation. Acta Cardiologica2012;67(4):407-14.">Gu 2012</a>, who compared single versus extensive antiarrhythmic use up to 2 months after ablation with 2‐ and 12‐month follow‐up. They, too, found reduced ATa recurrence (non‐significant versus extensive) in the early term that did not persist into long‐term follow‐up. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013765-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/urn:x-wiley:14651858:media:CD013765:CD013765-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA flow diagram." data-id="CD013765-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_t/tCD013765-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/full#CD013765-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013765-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/urn:x-wiley:14651858:media:CD013765:CD013765-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013765-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_t/tCD013765-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/full#CD013765-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013765-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/urn:x-wiley:14651858:media:CD013765:CD013765-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013765-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_t/tCD013765-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/full#CD013765-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013765-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/urn:x-wiley:14651858:media:CD013765:CD013765-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Class I and/or III antiarrhythmics versus control, Outcome 1: Class I and/or III ‐ Recurrence of atrial tachyarrhythmias ‐ 0 to 3 months after ablation" data-id="CD013765-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_t/tCD013765-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Class I and/or III antiarrhythmics versus control, Outcome 1: Class I and/or III ‐ Recurrence of atrial tachyarrhythmias ‐ 0 to 3 months after ablation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/references#CD013765-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013765-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/urn:x-wiley:14651858:media:CD013765:CD013765-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Class I and/or III antiarrhythmics versus control, Outcome 2: Class I and/or III ‐ Recurrence of atrial tachyarrhythmias ‐ &gt; 3 to 6 months after ablation" data-id="CD013765-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_t/tCD013765-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Class I and/or III antiarrhythmics versus control, Outcome 2: Class I and/or III ‐ Recurrence of atrial tachyarrhythmias ‐ &gt; 3 to 6 months after ablation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/references#CD013765-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013765-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/urn:x-wiley:14651858:media:CD013765:CD013765-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Class I and/or III antiarrhythmics versus control, Outcome 3: Class I and/or III ‐ Recurrence of atrial tachyarrhythmias ‐ &gt; 6 months after ablation" data-id="CD013765-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_t/tCD013765-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Class I and/or III antiarrhythmics versus control, Outcome 3: Class I and/or III ‐ Recurrence of atrial tachyarrhythmias ‐ &gt; 6 months after ablation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/references#CD013765-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013765-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/urn:x-wiley:14651858:media:CD013765:CD013765-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Class I and/or III antiarrhythmics versus control, Outcome 4: Class I and/or III ‐ Adverse events: Thromboembolic events ‐ 0 to 3 months after ablation" data-id="CD013765-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_t/tCD013765-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Class I and/or III antiarrhythmics versus control, Outcome 4: Class I and/or III ‐ Adverse events: Thromboembolic events ‐ 0 to 3 months after ablation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/references#CD013765-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013765-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/urn:x-wiley:14651858:media:CD013765:CD013765-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Class I and/or III antiarrhythmics versus control, Outcome 5: Class I and/or III ‐ Adverse events: Thromboembolic events ‐ &gt; 3 to 6 months after ablation" data-id="CD013765-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_t/tCD013765-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Class I and/or III antiarrhythmics versus control, Outcome 5: Class I and/or III ‐ Adverse events: Thromboembolic events ‐ &gt; 3 to 6 months after ablation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/references#CD013765-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013765-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/urn:x-wiley:14651858:media:CD013765:CD013765-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Class I and/or III antiarrhythmics versus control, Outcome 6: Class I and/or III ‐ Adverse events: Thromboembolic events ‐ &gt; 6 months after ablation" data-id="CD013765-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_t/tCD013765-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Class I and/or III antiarrhythmics versus control, Outcome 6: Class I and/or III ‐ Adverse events: Thromboembolic events ‐ &gt; 6 months after ablation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/references#CD013765-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013765-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/urn:x-wiley:14651858:media:CD013765:CD013765-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Class I and/or III antiarrhythmics versus control, Outcome 7: Class I and/or III ‐ Adverse events: Myocardial infarction ‐ &gt; 6 months after ablation" data-id="CD013765-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_t/tCD013765-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Class I and/or III antiarrhythmics versus control, Outcome 7: Class I and/or III ‐ Adverse events: Myocardial infarction ‐ &gt; 6 months after ablation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/references#CD013765-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013765-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/urn:x-wiley:14651858:media:CD013765:CD013765-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Class I and/or III antiarrhythmics versus control, Outcome 8: Class I and/or III ‐ Adverse events: Requirement for 1 or more hospitalisations for atrial tachyarrhythmia ‐ 0 to 3 months after ablation" data-id="CD013765-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_t/tCD013765-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Class I and/or III antiarrhythmics versus control, Outcome 8: Class I and/or III ‐ Adverse events: Requirement for 1 or more hospitalisations for atrial tachyarrhythmia ‐ 0 to 3 months after ablation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/references#CD013765-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013765-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/urn:x-wiley:14651858:media:CD013765:CD013765-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Class I and/or III antiarrhythmics versus control, Outcome 9: Class I and/or III ‐ All‐cause mortality ‐ 0 to 3 months after ablation" data-id="CD013765-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_t/tCD013765-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Class I and/or III antiarrhythmics versus control, Outcome 9: Class I and/or III ‐ All‐cause mortality ‐ 0 to 3 months after ablation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/references#CD013765-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013765-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/urn:x-wiley:14651858:media:CD013765:CD013765-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Class I and/or III antiarrhythmics versus control, Outcome 10: Class I and/or III ‐ All‐cause mortality ‐ &gt; 3 to 6 months after ablation" data-id="CD013765-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_t/tCD013765-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Class I and/or III antiarrhythmics versus control, Outcome 10: Class I and/or III ‐ All‐cause mortality ‐ &gt; 3 to 6 months after ablation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/references#CD013765-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013765-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/urn:x-wiley:14651858:media:CD013765:CD013765-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Class I and/or III antiarrhythmics versus control, Outcome 11: Class I and/or III ‐ All‐cause mortality ‐ &gt; 6 months after ablation" data-id="CD013765-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_t/tCD013765-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Class I and/or III antiarrhythmics versus control, Outcome 11: Class I and/or III ‐ All‐cause mortality ‐ &gt; 6 months after ablation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/references#CD013765-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013765-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/urn:x-wiley:14651858:media:CD013765:CD013765-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Class I and/or III antiarrhythmics versus control, Outcome 12: Class I and/or III ‐ Requirement for 1 or more repeat ablation ‐ 0 to 3 months after ablation" data-id="CD013765-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_t/tCD013765-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Class I and/or III antiarrhythmics versus control, Outcome 12: Class I and/or III ‐ Requirement for 1 or more repeat ablation ‐ 0 to 3 months after ablation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/references#CD013765-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013765-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/urn:x-wiley:14651858:media:CD013765:CD013765-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Class I and/or III antiarrhythmics versus control, Outcome 13: Class I and/or III ‐ Requirement for 1 or more repeat ablation ‐ &gt; 6 months after ablation" data-id="CD013765-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_t/tCD013765-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Class I and/or III antiarrhythmics versus control, Outcome 13: Class I and/or III ‐ Requirement for 1 or more repeat ablation ‐ &gt; 6 months after ablation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/references#CD013765-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013765-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/urn:x-wiley:14651858:media:CD013765:CD013765-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Class I antiarrhythmics versus control, Outcome 1: Class I ‐ Recurrence of atrial tachyarrhythmias ‐ 0 to 3 months after ablation" data-id="CD013765-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_t/tCD013765-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Class I antiarrhythmics versus control, Outcome 1: Class I ‐ Recurrence of atrial tachyarrhythmias ‐ 0 to 3 months after ablation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/references#CD013765-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013765-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/urn:x-wiley:14651858:media:CD013765:CD013765-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Class I antiarrhythmics versus control, Outcome 2: Class I ‐ Recurrence of atrial tachyarrhythmias ‐ &gt; 3 to 6 months after ablation" data-id="CD013765-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_t/tCD013765-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Class I antiarrhythmics versus control, Outcome 2: Class I ‐ Recurrence of atrial tachyarrhythmias ‐ &gt; 3 to 6 months after ablation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/references#CD013765-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013765-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/urn:x-wiley:14651858:media:CD013765:CD013765-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Class I antiarrhythmics versus control, Outcome 3: Class I ‐ Recurrence of atrial tachyarrhythmias ‐ &gt; 6 months after ablation" data-id="CD013765-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_t/tCD013765-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Class I antiarrhythmics versus control, Outcome 3: Class I ‐ Recurrence of atrial tachyarrhythmias ‐ &gt; 6 months after ablation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/references#CD013765-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013765-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/urn:x-wiley:14651858:media:CD013765:CD013765-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Class I antiarrhythmics versus control, Outcome 4: Class I ‐ Adverse events: Requirement for 1 or more hospitalisations for atrial tachyarrhythmia ‐ 0 to 3 months after ablation" data-id="CD013765-fig-0020" src="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_t/tCD013765-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Class I antiarrhythmics versus control, Outcome 4: Class I ‐ Adverse events: Requirement for 1 or more hospitalisations for atrial tachyarrhythmia ‐ 0 to 3 months after ablation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/references#CD013765-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013765-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/urn:x-wiley:14651858:media:CD013765:CD013765-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Class I antiarrhythmics versus control, Outcome 5: Class I ‐ Requirement for 1 or more repeat ablation ‐ 0 to 3 months after ablation" data-id="CD013765-fig-0021" src="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_t/tCD013765-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Class I antiarrhythmics versus control, Outcome 5: Class I ‐ Requirement for 1 or more repeat ablation ‐ 0 to 3 months after ablation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/references#CD013765-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013765-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/urn:x-wiley:14651858:media:CD013765:CD013765-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Class III antiarrhythmics versus control, Outcome 1: Class III ‐ Recurrence of atrial tachyarrhythmias ‐ 0 to 3 months after ablation" data-id="CD013765-fig-0022" src="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_t/tCD013765-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Class III antiarrhythmics versus control, Outcome 1: Class III ‐ Recurrence of atrial tachyarrhythmias ‐ 0 to 3 months after ablation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/references#CD013765-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013765-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/urn:x-wiley:14651858:media:CD013765:CD013765-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Class III antiarrhythmics versus control, Outcome 2: Class III ‐ Recurrence of atrial tachyarrhythmias ‐ &gt; 3 to 6 months after ablation" data-id="CD013765-fig-0023" src="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_t/tCD013765-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Class III antiarrhythmics versus control, Outcome 2: Class III ‐ Recurrence of atrial tachyarrhythmias ‐ &gt; 3 to 6 months after ablation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/references#CD013765-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013765-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/urn:x-wiley:14651858:media:CD013765:CD013765-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Class III antiarrhythmics versus control, Outcome 3: Class III ‐ Recurrence of atrial tachyarrhythmias ‐ &gt; 6 months after ablation" data-id="CD013765-fig-0024" src="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_t/tCD013765-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Class III antiarrhythmics versus control, Outcome 3: Class III ‐ Recurrence of atrial tachyarrhythmias ‐ &gt; 6 months after ablation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/references#CD013765-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013765-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/urn:x-wiley:14651858:media:CD013765:CD013765-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Class III antiarrhythmics versus control, Outcome 4: Class III ‐ Adverse events: Thromboembolic events ‐ 0 to 3 months after ablation" data-id="CD013765-fig-0025" src="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_t/tCD013765-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Class III antiarrhythmics versus control, Outcome 4: Class III ‐ Adverse events: Thromboembolic events ‐ 0 to 3 months after ablation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/references#CD013765-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013765-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/urn:x-wiley:14651858:media:CD013765:CD013765-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Class III antiarrhythmics versus control, Outcome 5: Class III ‐ Adverse events: Thromboembolic events ‐ &gt; 3 to 6 months after ablation" data-id="CD013765-fig-0026" src="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_t/tCD013765-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Class III antiarrhythmics versus control, Outcome 5: Class III ‐ Adverse events: Thromboembolic events ‐ &gt; 3 to 6 months after ablation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/references#CD013765-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013765-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/urn:x-wiley:14651858:media:CD013765:CD013765-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Class III antiarrhythmics versus control, Outcome 6: Class III ‐ Adverse events: Requirement for 1 or more hospitalisations for atrial tachyarrhythmia ‐ 0 to 3 months after ablation" data-id="CD013765-fig-0027" src="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_t/tCD013765-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Class III antiarrhythmics versus control, Outcome 6: Class III ‐ Adverse events: Requirement for 1 or more hospitalisations for atrial tachyarrhythmia ‐ 0 to 3 months after ablation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/references#CD013765-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013765-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/urn:x-wiley:14651858:media:CD013765:CD013765-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Class III antiarrhythmics versus control, Outcome 7: Class III ‐ All‐cause mortality ‐ 0 to 3 months after ablation" data-id="CD013765-fig-0028" src="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_t/tCD013765-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Class III antiarrhythmics versus control, Outcome 7: Class III ‐ All‐cause mortality ‐ 0 to 3 months after ablation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/references#CD013765-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013765-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/urn:x-wiley:14651858:media:CD013765:CD013765-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Class III antiarrhythmics versus control, Outcome 8: Class III ‐ All‐cause mortality ‐ &gt; 3 to 6 months after ablation" data-id="CD013765-fig-0029" src="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_t/tCD013765-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Class III antiarrhythmics versus control, Outcome 8: Class III ‐ All‐cause mortality ‐ &gt; 3 to 6 months after ablation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/references#CD013765-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013765-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/urn:x-wiley:14651858:media:CD013765:CD013765-CMP-003.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Class III antiarrhythmics versus control, Outcome 9: Class III ‐ Requirement for 1 or more repeat ablation ‐ 0 to 3 months after ablation" data-id="CD013765-fig-0030" src="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-003.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_t/tCD013765-CMP-003.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3: Class III antiarrhythmics versus control, Outcome 9: Class III ‐ Requirement for 1 or more repeat ablation ‐ 0 to 3 months after ablation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/references#CD013765-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/media/CDSR/CD013765/image_n/nCD013765-CMP-003.09.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013765-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Class I and/or III antiarrhythmics versus control for maintaining sinus rhythm after catheter ablation of atrial fibrillation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Class I and/or III antiarrhythmics versus control for maintaining sinus rhythm after catheter ablation of atrial fibrillation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patients or population:</b> Human trial participants undergoing ablation for atrial fibrillation </p> <p><b>Settings:</b> Community and healthcare settings </p> <p><b>Intervention:</b> Class I and/or III antiarrhythmics </p> <p><b>Comparison:</b> Standard medical therapy or placebo postablation not including Class I or III antiarrhythmics </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes at &gt; 3 to 6 months after ablation</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects*<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> <p><b>NNTB (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo or no treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Class I/III antiarrhythmic drugs</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recurrence of atrial tachyarrhythmias</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>453 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>385 per 1000</p> <p>(353 to 421)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.85 (0.78 to 0.93)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2591 (5 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁⨁◯</p> <p>MODERATE<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 15 (10 to 32)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events: thromboembolic events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> <p>(1 to 155)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 0.96 (0.06 to 15.50)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>212 (1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>VERY LOW<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events: myocardial infarction</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No data available at &gt; 3 to 6 months, but available at &gt; 6 months<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events: new diagnosis of heart failure</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No data available at any time point<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events: requirement for 1 or more hospitalisations for atrial tachyarrhythmia</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No data available at &gt; 3 to 6 months, but available at 0 to 3 months<sup>e</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000</p> <p>(1 to 357)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 1.00 (0.06 to 16.24)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 (1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯</p> <p>LOW<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Requirement for 1 or more repeat ablations</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No data available at &gt; 3 to 6 months, but available at 0 to 3 months and &gt; 6 months<sup>g</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% confidence interval) is calculated based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Outcomes at time points other than primary time point of interest (&gt; 3 to 6 months)</b> </p> <p><sup>a</sup>Recurrence of atrial tachyarrhythmias: 0 to 3 months: RR 0.74 (0.59 to 0.94); &gt; 6 months: RR 1.14 (0.84 to 1.55).<br/><sup>b</sup>Thromboembolic events: 0 to 3 months: not estimable; &gt; 6 months: Peto OR 2.74 (0.39 to 19.5).<br/><sup>c</sup>Myocardial infarction: 0 to 3 months: not available; &gt; 6 months: Peto OR 1.01 (0.06 to 16.09).<br/><sup>d</sup>New diagnosis of heart failure: 0 to 3 months: not available; &gt; 6 months: not available.<br/><sup>e</sup>Hospitalisations for atrial tachyarrhythmia: 0 to 3 months: RR 0.43 (0.28 to 0.64); &gt; 6 months: not available.<br/><sup>f</sup>All‐cause mortality: 0 to 3 months: Peto OR 0.13 (0.00 to 6.57); &gt; 6 months: Peto OR 1.50 (0.26 to 8.68).<br/><sup>g</sup>Repeat ablation: 0 to 3 months: RR 1.10 (0.61 to 2.00); &gt; 6 months: RR 0.95 (0.79 to 1.13). </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level for risk of bias, regarding exclusion of participants lost to follow‐up in <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a>, and randomisation generation and allocation concealment in <a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. ">Kaitani 2016</a>.<br/><sup>2</sup>Downgraded for imprecision (two levels) (95% CI 0.06 to 15.5, which is consistent with both appreciable benefit and appreciable harm, and low event numbers) and risk of bias, specifically concerning exclusion of participants lost to follow‐up in <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a> (one level).<br/><sup>3</sup>Downgraded for imprecision (one level) (95% CI 0.06 to 16.2, which is consistent with both appreciable benefit and appreciable harm) and risk of bias, specifically concerning exclusion of participants lost to follow‐up in <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a> (one level). </p> <p>Outcomes have been downgraded twice for imprecision where there are few events and the 95% CI include both appreciable benefit and harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Class I and/or III antiarrhythmics versus control for maintaining sinus rhythm after catheter ablation of atrial fibrillation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/full#CD013765-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013765-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Class I antiarrhythmics versus control for maintaining sinus rhythm after catheter ablation of atrial fibrillation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Class I antiarrhythmics versus control for maintaining sinus rhythm after catheter ablation of atrial fibrillation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patients or population:</b> Human trial participants undergoing ablation for atrial fibrillation </p> <p><b>Settings:</b> Community and healthcare settings </p> <p><b>Intervention:</b> Class I antiarrhythmics </p> <p><b>Comparison:</b> Standard medical therapy or placebo postablation not including Class I or III antiarrhythmics </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes at &gt; 3 to 6 months after ablation</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects*<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo or no treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Class I antiarrhythmic drugs</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recurrence of atrial tachyarrhythmias</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>238 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>129 per 1000</p> <p>(60 to 283)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.54 (0.25 to 1.19)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125 (1 trial)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>LOW<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events: thromboembolic events</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events: myocardial infarction</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events: new diagnosis of heart failure</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events: requirement for 1 or more hospitalisations for atrial tachyarrhythmia</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available at &gt; 3 to 6 months, but available at 0 to 3 months<sup>e</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available<sup>f</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Requirement for 1 or more repeat ablation</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available at &gt; 3 to 6 months, but available at 0 to 3 months<sup>g</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% confidence interval) is calculated based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Outcomes at time points other than primary time point of interest (&gt; 3 to 6 months)</b> </p> <p><sup>a</sup>Recurrence of atrial tachyarrhythmias: 0 to 3 months: RR 0.88 (0.64 to 1.20); &gt; 6 months: RR 0.87 (0.57 to 1.32).<br/><sup>b</sup>Thromboembolic events: 0 to 3 months: not available; &gt; 6 months: not available.<br/><sup>c</sup>Myocardial infarction: 0 to 3 months: not available; &gt; 6 months: not available.<br/><sup>d</sup>New diagnosis of heart failure: 0 to 3 months: not available; &gt; 6 months: not available.<br/><sup>e</sup>Hospitalisations for atrial tachyarrhythmia: 0 to 3 months: RR 0.34 (0.01 to 8.28); &gt; 6 months: not available.<br/><sup>f</sup>All‐cause mortality: 0 to 3 months: not available; &gt; 6 months: not available.<br/><sup>g</sup>Repeat ablation: 0 to 3 months: RR 0.88 (0.51 to 1.53); &gt; 6 months: not available. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded two levels for imprecision (95% CI 0.25 to 1.19, which is consistent with both appreciable benefit and appreciable harm) and not meeting the optimal information size. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Class I antiarrhythmics versus control for maintaining sinus rhythm after catheter ablation of atrial fibrillation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/full#CD013765-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013765-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Class III antiarrhythmics versus control for maintaining sinus rhythm after catheter ablation of atrial fibrillation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Class III antiarrhythmics versus control for maintaining sinus rhythm after catheter ablation of atrial fibrillation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patients or population:</b> Human trial participants undergoing ablation for atrial fibrillation </p> <p><b>Settings:</b> Community and healthcare settings </p> <p><b>Intervention:</b> Class III antiarrhythmics </p> <p><b>Comparison:</b> Standard medical therapy or placebo postablation not including Class I or III antiarrhythmics </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes at &gt; 3 to 6 months after ablation</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects*<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo or no treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Class III antiarrhythmic drugs</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recurrence of atrial tachyarrhythmias</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>413 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>339 per 1000</p> <p>(256 to 450)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.82 (0.62 to 1.09)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>318 (2 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯</p> <p>LOW<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events: thromboembolic events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> <p>(1 to 155)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 0.96 (0.06 to 15.50)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>212 (1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯</p> <p>VERY LOW<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events: myocardial infarction</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events: new diagnosis of heart failure</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events: requirement for 1 or more hospitalisations for atrial tachyarrhythmia</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available at &gt; 3 to 6 months, but available at 0 to 3 months<sup>e</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000</p> <p>(0 to 66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 0.13 (0.00 to 6.57)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>212 (1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯</p> <p>VERY LOW<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Requirement for 1 or more repeat ablation</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>No data available at &gt; 3 to 6 months, but available at 0 to 3 months<sup>g</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% confidence interval) is calculated based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Outcomes at time points other than primary time point of interest (&gt; 3 to 6 months)</b> </p> <p><sup>a</sup>Recurrence of atrial tachyarrhythmias: 0 to 3 months: RR 0.76 (0.50 to 1.16); &gt; 6 months: RR 1.95 (1.29 to 2.94).<br/><sup>b</sup>Thromboembolic events: 0 to 3 months: not estimable; &gt; 6 months: not available.<br/><sup>c</sup>Myocardial infarction: 0 to 3 months: not available; &gt; 6 months: not available.<br/><sup>d</sup>New diagnosis of heart failure: 0 to 3 months: not available; &gt; 6 months: not available.<br/><sup>e</sup>Hospitalisations for atrial tachyarrhythmia: 0 to 3 months: RR 0.40 (0.26 to 0.63); &gt; 6 months: not available.<br/><sup>f</sup>All‐cause mortality: 0 to 3 months: Peto OR 1.00 (0.06 to 16.24); &gt; 6 months: not available.<br/><sup>g</sup>Repeat ablation: 0 to 3 months: RR 1.18 (0.66 to 2.11); &gt; 6 months: not available. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for imprecision (one level) (95% CI 0.62 to 1.09, which is consistent with both appreciable benefit and appreciable harm) and risk of bias, specifically concerning exclusion of participants lost to follow‐up in <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a> (one level).<br/><sup>2</sup>Downgraded for imprecision (two levels) (95% CI 0.06 to 15.5, which is consistent with both appreciable benefit and appreciable harm, and low event numbers) and risk of bias concerning exclusion of participants lost to follow‐up in <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a> (one level).<br/><sup>3</sup>Downgraded for imprecision (two levels) (95% CI 0.00 to 6.57, which is consistent with both appreciable benefit and appreciable harm, and low event numbers) and risk of bias concerning exclusion of participants lost to follow‐up in <a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. ">Darkner 2014</a> (one level). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Class III antiarrhythmics versus control for maintaining sinus rhythm after catheter ablation of atrial fibrillation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/full#CD013765-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013765-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Participant characteristicsa </span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Age</b> </p> <p><b>(years)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sex</b> </p> <p><b>(% male)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mean AF duration</b> </p> <p><b>(months)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mean left atrial diameter</b> </p> <p><b>(cm)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of prior antiarrhythmics</b> </p> <p><b>(mean ±SD)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Previous AF ablations</b> </p> <p><b>(%)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hypertension</b> </p> <p><b>(%)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Diabetes</b> </p> <p><b>(%)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mean LVEF</b> </p> <p><b>(%)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013765-bbs2-0009" title="TurcoP , De SimoneA , La RoccaV , IulianoA , CapuanoV , AstaritaC , et al. Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation. Pacing and Clinical Electrophysiology2007;30:S112-5. "><b>Turco 2007</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.80</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.0</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. "><b>Roux 2009</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.60 ±1.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.5</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. "><b>Darkner 2014</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.15 ±0.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50.5</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. "><b>Hayashi 2014</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.80</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00 ±1.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.5</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. "><b>Lodziński 2014</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. "><b>Mohanty 2015</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.75</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54.5</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. "><b>Ad 2016</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.05</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54.8</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. "><b>Kaitani 2016</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.90</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.3</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. "><b>Tarasov 2017</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>( ‐ ) = not reported</p> <p>Abbreviations: AF: atrial fibrillation; LVEF: left ventricular ejection fraction; SD: standard deviation </p> <p><sup>a</sup>Abstracted or calculated total average from all relevant subgroups. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Participant characteristicsa </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/full#CD013765-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013765-tbl-0005"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Ablation approach and strategy</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Trial</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Approach</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ablation strategy</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013765-bbs2-0001" title="AdN , HolmesSD , ShumanDJ , PritchardG , MillerCE . Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery2015;151(3):798-803. "><b>Ad 2016</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgical ablation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cox maze III/IV lesion set, utilised in all but 1 participant</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013765-bbs2-0002" title="DarknerS , ChenX , HansenJ , PehrsonS , JohannessenA , NielsenJB , et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal2014;35(47):3356–64. "><b>Darkner 2014</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percutaneous ablation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary vein isolation/wide antral circumferential ablation</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013765-bbs2-0003" title="HayashiM , MiyauchiY , IwasakiY , YodogawaK , TsuboiI , UetakeS , et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace2014;16(8):1160–7. "><b>Hayashi 2014</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percutaneous ablation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary vein isolation</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013765-bbs2-0004" title="KaitaniK , InoueK , KoboriA , NakazawaY , OzawaT , KurotobiT , et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. European Heart Journal2016;37(7):610-8. "><b>Kaitani 2016</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percutaneous ablation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary vein isolation/wide antral circumferential ablation</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013765-bbs2-0005" title="LodzinskiP , KiliszekM , KozlukE , PiatkowskaA , BalsamP , KochanowskiJ , et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal2014;14(21):384-91. "><b>Lodziński 2014</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percutaneous ablation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary vein isolation</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013765-bbs2-0006" title="MohantyS , Di BiaseL , MohantyP , TrivediC , SantangeliP , BaiR , et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm2014;12(3):477-83. "><b>Mohanty 2015</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percutaneous ablation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary vein antral isolation + posterior wall isolation + defragmentation + extra pulmonary vein triggers </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013765-bbs2-0007" title="RouxJF , ZadoE , CallansDJ , GarciaF , LinD , MarchlinskiFE , et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation2009;120(12):1036–40. "><b>Roux 2009</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percutaneous ablation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary vein isolation + extra pulmonary vein triggers</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013765-bbs2-0008" title="TarasovAV , DavtyanKV , MartsevichSY . Comparison of effectiveness of antiarrhythmic therapies in postoperative period of pulmonary vein ostia catheter isolation for prevention of early recurrences of atrial tachyarrhythmias in the PROOF study. Rational Pharmacotherapy in Cardiology2017;13(1):18-24. "><b>Tarasov 2017</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percutaneous ablation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary vein ostial isolation</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013765-bbs2-0009" title="TurcoP , De SimoneA , La RoccaV , IulianoA , CapuanoV , AstaritaC , et al. Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation. Pacing and Clinical Electrophysiology2007;30:S112-5. "><b>Turco 2007</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percutaneous ablation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary vein isolation + mitral isthmus + cavo‐tricuspid isthmus</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Ablation approach and strategy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/full#CD013765-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013765-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Class I and/or III antiarrhythmics versus control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Class I and/or III ‐ Recurrence of atrial tachyarrhythmias ‐ 0 to 3 months after ablation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3046</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.59, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Class I and/or III ‐ Recurrence of atrial tachyarrhythmias ‐ &gt; 3 to 6 months after ablation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.78, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Class I and/or III ‐ Recurrence of atrial tachyarrhythmias ‐ &gt; 6 months after ablation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.84, 1.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Class I and/or III ‐ Adverse events: Thromboembolic events ‐ 0 to 3 months after ablation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Class I and/or III ‐ Adverse events: Thromboembolic events ‐ &gt; 3 to 6 months after ablation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.06, 15.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Class I and/or III ‐ Adverse events: Thromboembolic events ‐ &gt; 6 months after ablation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2038</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.74 [0.39, 19.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Class I and/or III ‐ Adverse events: Myocardial infarction ‐ &gt; 6 months after ablation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2038</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.06, 16.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Class I and/or III ‐ Adverse events: Requirement for 1 or more hospitalisations for atrial tachyarrhythmia ‐ 0 to 3 months after ablation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>448</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.28, 0.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Class I and/or III ‐ All‐cause mortality ‐ 0 to 3 months after ablation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.00, 6.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Class I and/or III ‐ All‐cause mortality ‐ &gt; 3 to 6 months after ablation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.06, 16.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Class I and/or III ‐ All‐cause mortality ‐ &gt; 6 months after ablation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2038</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.26, 8.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Class I and/or III ‐ Requirement for 1 or more repeat ablation ‐ 0 to 3 months after ablation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>567</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.61, 2.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Class I and/or III ‐ Requirement for 1 or more repeat ablation ‐ &gt; 6 months after ablation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.79, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Class I and/or III antiarrhythmics versus control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/references#CD013765-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013765-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Class I antiarrhythmics versus control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Class I ‐ Recurrence of atrial tachyarrhythmias ‐ 0 to 3 months after ablation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.64, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Class I ‐ Recurrence of atrial tachyarrhythmias ‐ &gt; 3 to 6 months after ablation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.25, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Class I ‐ Recurrence of atrial tachyarrhythmias ‐ &gt; 6 months after ablation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.57, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Class I ‐ Adverse events: Requirement for 1 or more hospitalisations for atrial tachyarrhythmia ‐ 0 to 3 months after ablation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Class I ‐ Requirement for 1 or more repeat ablation ‐ 0 to 3 months after ablation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.51, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Class I antiarrhythmics versus control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/references#CD013765-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013765-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Class III antiarrhythmics versus control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Class III ‐ Recurrence of atrial tachyarrhythmias ‐ 0 to 3 months after ablation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.50, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Class III ‐ Recurrence of atrial tachyarrhythmias ‐ &gt; 3 to 6 months after ablation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.62, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Class III ‐ Recurrence of atrial tachyarrhythmias ‐ &gt; 6 months after ablation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [1.29, 2.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Class III ‐ Adverse events: Thromboembolic events ‐ 0 to 3 months after ablation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Class III ‐ Adverse events: Thromboembolic events ‐ &gt; 3 to 6 months after ablation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.06, 15.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Class III ‐ Adverse events: Requirement for 1 or more hospitalisations for atrial tachyarrhythmia ‐ 0 to 3 months after ablation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.26, 0.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Class III ‐ All‐cause mortality ‐ 0 to 3 months after ablation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.06, 16.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Class III ‐ All‐cause mortality ‐ &gt; 3 to 6 months after ablation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.00, 6.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.9 Class III ‐ Requirement for 1 or more repeat ablation ‐ 0 to 3 months after ablation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>505</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.66, 2.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Class III antiarrhythmics versus control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013765.pub2/references#CD013765-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013765.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD013765-note-0011">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD013765-note-0035">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013765-note-0029">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013765-note-0033">Français</a> </li> <li class="section-language"> <a class="" href="ko#CD013765-note-0020">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD013765-note-0026">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD013765-note-0030">Polski</a> </li> <li class="section-language"> <a class="" href="ro#CD013765-note-0034">Română</a> </li> <li class="section-language"> <a class="" href="ru#CD013765-note-0017">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD013765-note-0023">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013765-note-0014">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013765\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013765\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013765\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013765\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013765\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013765\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013765\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013765\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013765\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013765\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013765\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013765\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013765\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013765\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013765\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013765\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013765\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013765\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=wbKFI7vu&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013765.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013765.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013765.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013765.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013765.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719442611"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013765.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719442615"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013765.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918de8dc8b4af55b',t:'MTc0MDcxOTQ0Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 